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Abstract 
Background and Aims 
Tenofovir disoproxil fumarate (TDF) and lamivudine (3TC) or emtricitabine (FTC) combined with 
efavirenz is the predominant first-line antiretroviral regimen in the Southern African region.  
Resistance to TDF and 3TC/FTC is largely through the occurrence of the drug resistance 
mutations (DRMs) K65R and M184V, respectively.  Preliminary data from a large laboratory-based 
dataset of HIV drug resistance that showed a high prevalence of these mutations in patients who 
received the TDF regimen also revealed a significant co-occurrence of A62V with M184V and 
K65R.  The aim of this study was to investigate the functional interaction and effect on viral fitness 
that A62V has when it co-occurs with M184V and K65R reverse transcriptase mutations in HIV-1 
Subtype C. 
Materials and Methods 
Using Infusion™ cloning and site-directed mutagenesis techniques, eight full-length genome 
infectious clones containing the HIV-1 subtype C polymerase gene were synthesised having all 
combinations of DRMs - A62V, M184V and K65R, either being present or absent. The mutations in 
these constructs were verified by sequencing.  The constructs were transfected into 293T cells for 
virion production and harvested virus was infected in the TZM-bl cell line in head to head growth 
competition experiments and assayed for growth kinetics using an allele-specific quantitative real-
time polymerase chain reaction (PCR) assay. 
Results 
The growth competition experiment between two viruses (A62V+K65R+M184V vs K65R+M184V) 
evaluated by taking the mean of 3 biological replicates in the assay in the absence of antiretroviral 
drugs, revealed that A62V mutation has no significant impact on fitness (Wilcoxon signed rank test 
p-value = 0.56). The overall coefficient of variation (CV) in the experiment was 12.8% indicating the 
high reproducibility of the growth competition assay using real-time PCR measurement of relative 
growth.  
Conclusion and recommendations 
A62V mutation has no effect on fitness when it co-occurs with M184V and K65R. The co-
occurrence with M184V and K65R remains unexplained and might be due to an effect on TDF 
resistance in combination with K65R.This requires investigation in future studies as TDF regimens 
are part of 1st line therapy in many Sub-Saharan countries in the treatment of HIV-1. Finally, the 
cloning and mutagenesis techniques used coupled with a very sensitive and reproducible real-time 
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quantitative PCR assay provide an efficient system for detection of mutation fitness interactions 
and can be used in any future work to study HIV mutation fitness interactions. 
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Opsomming 
Agtergrond en doel 
Tenofovir disoproksil fumaraat (TDF) en lamivudien (3TC) of emitricitabine (FTC) gekombineer met 
efavirenz is die oorheersende eerste lyn antiretrovirale regimen in die Suider-Afrikaanse streek. 
Weerstand teen TDF en 3TC / FTC is grootliks deur die voorkoms van die middel-- 
weerstandigheid-mutasies (DRM's) K65R en M184V, onderskeidelik. Voorlopige data van 'n groot 
laboratorium- gebaseerde datastel van MIV middel-weerstand het bewys dat daar 'n hoë voorkoms 
van hierdie mutasies is in pasiënte wat die tenofovir regimen ontvang en het ook 'n beduidende 
mede-voorkoms van A62V met M184V en K65R onthul. Die doel van hierdie studie was om die 
funksionele interaksie en invloed op virale fiksheid te ondersoek wat A62V het wanneer dit 
voorkom saam met M184V en K65R trutranskriptase mutasies in MIV-1 Subtype C. 
Materiale en metodes 
Infusion ™ kloning en mutagenese tegnieke is gebruik om 8 vollengte MIV rekombinante klone te 
verkry met alle kombinasies van DRM's, A62V, M184V en K65R, hetsy teenwoordig of afwesig en 
die mutasies in hierdie konstrukte is bevestig deur nukleinsuurbasisbaarvolgordebepaling. Die 
konstrukte was getransfekteer  in 293T selle vir virion produksie. Virus supernatant is geoes  en 
die TZM-bl sellyn is geinfekteer en gebruik in kop-aan-kop groei kompetisie 
eksperimente;virusproduksie is getoets met behulp van 'n alleel-spesifieke in-huis kwantitatiewe 
reële-tyd polimerase kettingreaksie (PKR) om die groei kinetika te ondersoek. 
Resultate 
Die groei kompetisie eksperiment tussen twee virusse (A62V + K65R + M184V vs K65R + M184V) 
wat geëvalueer was deur die neem van die gemiddelde van 3 biologiese herhalings in die 
teenwoordigheid van anti-retrovirale middels, het getoon dat A62V mutasie het geen beduidende 
impak op fiksheid (“Wilcoxon singned rank” toets p-waarde = 0.56). Die algehele koëffisiënt van 
variasie (KV) in die eksperiment was 12,8% wat aandui op die hoë herhaalbaarheid van die  groei-
kompetisie eksperiment met  reële tyd PKR kwantifisering van relatiewe groeikoers. 
Gevolgtrekking en aanbevelings 
A62V mutasie het geen effek op fiksheid wanneer dit voorkom met M184V en K65R nie. Die 
gesamentlike voorkoms van A62V met M184V en K65R bly onverklaarbaar, maar dit mag weens 
verhoogde weerstandigheid teen TDF wees wanneer A62V met K65R voorkom. Om dit te verklaar  
benodig verdere studies aangesien TDF- gebaseerde kombinasieterapie in baie Sub-Saharan 
lande gebruik word vir 1ste-lyn  behandeling van MIV-1.Ten slotte, die kloning en mutageniese 
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tegnieke, wat gebruik is, tesame met 'n baie sensitiewe en herhaalbare reële-tyd kwantitatiewe 
PKR toets verleen  'n doeltreffende benaderingom fiksheids interaksies te ondersoek. 
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Literature Review 
Chapter 1- Introduction 
 
1.1 Introduction to HIV drug resistance and viral fitness 
HIV (Human Immunodeficiency virus) the causative agent of Acquired Immunodeficiency 
Syndrome (AIDS) undergoes rapid mutation of its viral genome (Mansky and Temin, 1995).The 
high mutation rate, a function of the lack of proofreading of HIV reverse transcriptase and high 
replication rate, contributes to the evolution of drug resistance mutations (DRMs). Viral species 
harbouring DRMs (referred to as drug-resistant variants (DRVs) throughout this review) are often 
found in infected patients with elevated viral loads while receiving combination antiretroviral 
therapy (cART). The emergence of drug resistance in patients is multifactorial and encompasses 
pharmacological, host and adherence factors (Cortez and Malderelli, 2011). 
Before the availability of cART regimens, HIV treatment was based on monotherapy (Fischl et al., 
1987). Zidovudine (AZT) was the first licenced antiretroviral drug and was Federal Drug Authority 
(FDA) approved in 1987 (P.H.S., 1987). As monotherapy, it did not result in sustained therapy 
success and in 1991/1992 antiretroviral resistance was shown to be the cause of failure (Wainberg 
et al., 1991). Only when cART became the standard of care in 1996/1997, therapy achieved long-
term success in the majority of patients (Egger et al., 1997; Gulick et al., 1997).This was initially 
referred to as highly active antiretroviral therapy (HAART) and consisted of a combination of at 
least three antiretroviral drugs, either two nucleoside reverse transcriptase inhibitors (NRTIs) that 
were analogues of different native nucleosides combined with either a protease inhibitor or a non-
nucleoside reverse transcriptase inhibitor (NNRTI) (Arts et al., 2012). There are several classes of 
antiretroviral (ARV) drugs which target various stages of HIV-1 replication: nucleoside reverse 
transcriptase inhibitors (NRTIs); non-nucleoside reverse transcriptase inhibitors (NNRTIs); 
protease inhibitors (PIs); entry inhibitors; inhibitors of co-receptors and integrase inhibitors (Chen 
et al., 2007). 
In South Africa, where the dominant strain of the virus is HIV-1 subtype C, an estimated 6.8 million 
individuals are infected with the virus. HIV infected individuals in South Africa represent 
approximately 20% of the number infected worldwide and approximately 28% of the number of 
people living with the virus in Sub-Saharan Africa (UNAIDS, 2014a). South Africa started its 
national ARV rollout program in 2004 (D.o.H., 2004) and presently, an estimate of 50% of the 
number of individuals in South Africa living with HIV are on ARVs (UNAIDS, 2014b).  
Stellenbosch University  https://scholar.sun.ac.za
2 
 
The current standardized regimens for 1st line therapy for adults and adolescents include tenofovir 
disoproxil fumarate (TDF), lamivudine (3TC) or emtricitabine (FTC), and efavirenz (EFV) or 
nevirapine (NVP) (D.o.H., 2010). Despite the success of cART in arresting viral replication to 
undetectable levels (below 50 copies/ml as detected by viral load assays) and conferring partial 
immune reconstitution (Autran et al., 1997), development of drug resistance is likely due to a low 
genetic barrier of  the 1st line therapy regimen. 
South Africa as a low to middle-income country faces clinical care and laboratory monitoring of 
more than three million people on cART, and the situation places the country with an enormous 
service-delivery challenge. Continued therapy success is dependent on continuous drug supply, 
patient-friendly health services and early detection of the failure in patients with inadequate 
adherence to prevent drug resistance (Stadeli and Richman, 2013). However, in the case of 
systemic health care failure or individual non-adherence, patients who have virological failure are 
at high risk of development of DRMs (Machado et al., 2009; Hosseinipour et al., 2009; Neogi et al., 
2011).  
The nomenclature for describing any particular DRM is according to the International Union of Pure 
and Applied Chemistry (IUPAC). Mutations are numbered according to the amino acid position 
within the relevant protein, with the native amino acid abbreviation preceding the number and the 
mutated amino acid following the number. For example, M184V indicates a substitution of 
Methionine (M) with Valine (V) at position 184 of HIV reverse transcriptase (RT) enzyme (Stott et 
al., 2012). 
DRMs are usually non-polymorphic (rarely observed in untreated patients). DRMs that are present 
could either be a result of transmission from one individual to another individual (transmitted drug 
resistance) or be acquired as a result of drug resistance selection or HIV evolution during therapy 
failure (acquired drug resistance) (Pennings, 2013 Kuritzkes, 2004). In Sub-Saharan Africa, 
acquired drug-resistance ranges from 53%-90% for patients failing 1st line therapy within the first 
12 months after initiation of ARV therapy (Gupta et al., 2012) compared with a prevalence of  
approximately 7-17% of transmitted drug resistance (Pennings, 2013). Patients who fail therapy 
with acquired drug-resistance usually have dual-class resistance whereas multi-class drug 
resistance (MDR) to NRTIs, NNRTI and PIs is still relatively rare in Sub-Saharan Africa (Pennings, 
2013). 
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1.2 HIV-1 structure, replication and Pathogenesis 
A brief review of the structure, replication and pathogenesis of HIV is given below. This section is 
followed by a section reviewing concepts related to antiretroviral therapy, mechanism of HIV drug 
resistance, measures for viral fitness and drug resistance testing. 
1.2.1 HIV-1 Structure and replication 
HIV-1 is classified under the Retroviridae family and sub-classified under the Lentivirus genus. 
There are two HIV species, HIV-1 and HIV-2. HIV-1 is divided into four groups M (Main), O 
(Outlier), N (New) and group P (Vallari et al., 2009). For HIV-2, there are eight groups (A-H) 
(Etienne et al., 2011). Group M genetic diversity has been well characterised and includes nine 
subtypes (designated A - D, F - H and J - K), an estimated 54 circulating recombinant forms 
(CRFs) and emerging Unique recombinant forms (URFs) (Parczewski, 2013) 
HIV-1 mature virions are approximately 100-120nm in diameter and have a spiked lipid bilayer 
membrane, which includes embedded structural envelope proteins: gp120 and gp41. Internal 
structural proteins include the matrix protein (p17); the capsid protein (p24) and a nucleocapsid 
protein (p7). Enclosed in the capsid are virus-encoded enzymes; protease, a homodimer; reverse 
transcriptase, a heterodimer and integrase, all essential for viral replication; and two copies of its 
~9.2kb positive-stranded RNA genome (Sierra et al., 2005). HIV’s genomic features are a common 
characteristic of most lentiviruses and these features (Figure 1a), include structural genes: the 
group antigen (gag), the envelope (env) and the polymerase (pol) gene. Non-structural regulatory 
genes include tat (trans-activator of transcription); rev (regulator of viral expression) and non- 
structural accessory genes include: Nef (negative factor); vpr (viral protein r) and vpu (viral protein 
u). The HIV genome also includes non-coding sequences (Figure 1a): The Unique 5’ (U5), Unique 
3’ (U3) and Repeat (R) regions which collectively define the 5’ and 3’ long terminal repeats (LTRs) 
at the ends of the viral genome (Joshi and Joshi, 1996). Other non-coding sequences segments 
include the primer binding site (PBS), transactivation response element (TAR), packaging signal 
(ᵠ), and cis-acting repressive sequences (CRSs), polypurine tract (PPT) (Wurtzer et al., 2005), 
Rev-responsive element (RRE) and the dimer linkage structure (DLS) (Paillart et al., 1996). 
HIV-1 replication cycle initiates after the concurrent binding of the viral envelope gp120 trimer with 
the CD4 and CCR5/ CXCR4 cell receptors (Michael, 1999). The CCR5/CXCR4 functions as a co-
receptor in the binding of the virus allowing the viral gp41 transmembrane to fuse the viral 
envelope with the membrane of the cell in a pH-dependent manner. An invagination reaction then 
follows leading to the subsequent docking of the nucleocapsid into the cytoplasm and uncoating of 
the viral genome. Uncoating occurs under the influence of cellular factors (Sierra et al., 2005; Joshi 
and Joshi 1996). 
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The viral genome is reverse transcribed by the HIV RT enzyme into double-stranded DNA (dsDNA) 
in a series of strand displacement reactions that creates an overlap termed central DNA flap 
(Zennou et al., 2000) on one of the DNA strands which is essential for nuclear import. The central 
DNA flap facilitates formation of the pre-integration complex (PIC) which includes vpr, HIV 
integrase, matrix protein and host proteins (Zennou et al., 2000). Vpr promotes the nuclear 
importation of the PIC via the nuclear pore and the viral DNA is preferentially integrated into active 
cellular genes by HIV integrase (Schroder et al., 2002). Integrated proviral DNA is transcribed by 
cellular DNA-dependent RNA polymerase II. Unintegrated proviral DNA can exist within the cell 
nucleus as 2-LTR circular, 1-LTR circular and linear forms of DNA and provide the initial 
expression of tat, nef and rev proteins until their full expression by integrated proviral DNA (Wu, 
2004). 
The expression of tat coupled with the presence of transcription factors such as NF-κβ, EBP-1, 
TFIIP and SP1 within the host cell, initiates downstream expression of the integrated viral genome 
from the 5’ LTR end and lead to the expression of viral enzymes and proteins (Joshi and Joshi, 
1996). However, in the absence of transcription factors, HIV establishes latency (Shan et al., 2012; 
Eisele and Siliciano, 2012) which contributes to the persistence of viral strains carrying DRMs 
harboured in long-lived cells such as CD4 memory T lymphocytes (Volberding and Deeks, 2010). If 
transcription of the proviral DNA occurs, three classes of mRNA transcripts, multiply spliced, singly 
spliced and full-length transcripts, are synthesized (Wu, 2004). Briefly, the gag, pol and env mRNA 
transcripts are singly spliced mRNA transcripts which when translated give rise to the gag 
precursor (p55), gag-pol precursor (p160) and membrane precursor (gp160) proteins respectively 
but are preceded by singly spliced nef and multiply spliced tat, rev, vpr and vpu mRNA transcripts 
(Joshi and Joshi, 1996). Increased rev expression later in the viral life cycle results in increased 
nuclear export of singly spliced and full-length mRNA transcripts into the cytoplasm of the cell, 
where ribosomal translation of mRNA to proteins take place (Sierra et al., 2005). Gag and env 
derived structural proteins then undergo post-translation modification via proteolytic cleavage with 
protease and are eventually assembled to form the structural components of the virion particle 
(Figure 1b). The virion is also packaged with its primer (tRNA3
Lys) and two copies of its RNA 
genome and gag-pol derived viral enzymes (Figure 1b).The virion is subsequently enclosed in a 
vesicle and transported to the cell membrane where it buds off (deriving its lipid bilayer membrane 
from the host’s membrane) to begin another round of infection. The membrane is embedded with 
env derived proteins that include gp41 transmembrane glycoprotein stalks and gp120 surface 
protein (Figure 1b). The gp41 stalks are estimated to be 72 in total per particle (Gelderblom et al., 
1987). 
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Figure 1- (a) HIV genomic structure. (b) HIV cross-sectional map of fully assembled infectious viral 
protein (Photo adapted and reproduced with permission (see Addendum A1) from Joshi and 
Joshi, 1996) 
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1.2.2 HIV-1 target cell infection and pathogenesis 
HIV-1 targets both immune and non-immune cells that can either be dividing and non-dividing cells 
of the human body. CD4 T-cells are the primary targets of HIV-1 (Bowers et al., 1997; 
Pattanapanyasat and Thakur 2005). Among the list of immune dividing cells are thymic lymphocyte 
precursors, follicular dendritic cells and B-cells. Non-dividing immune cells include Langerhans 
cells and monocytes or macrophages (Aldrovandi, 1997).  
In the absence of antiretroviral therapy, the course of HIV pathogenesis follows three stages (Naif, 
2013). The first is the acute phase that is characterised by a high viraemia (2-8 weeks), followed by 
a clinically latent or asymptomatic stage (2-7 years). The last stage is a symptomatic stage which 
ends in progression to AIDS (Volberding and Deeks, 2010). In the progression to AIDS, there is a 
rebound of viraemia and the virus changes from CCR5 co-receptor usage to CXCR4 in 
approximately 50% of infected patients, leaving most treatment naïve patients with a median 
survival time of less than ten years (Arien et al., 2006). 
HIV-1 infection is associated with chronic immune activation and dysregulation of the immune 
system (Ipp et al., 2013; Freguja et al., 2012). Following successful infection of -permissive cells 
(such as dendritic cells that migrate to lymph nodes), HIV-1 affects the GALT (gut associated 
lymphoid tissue) and extensive damage to this tissue leads to translocation of microbial products 
into the blood stream causing the release of redox species that affect red blood cells (HIV-
associated anaemia) and the release of proinflammatory cytokines such as IL 7, IL 10 and IFN-γ. 
IL 10 is known to induce the apoptotic receptor PD1 on macrophages and can inhibit T-cell 
function by engaging the T-cell receptor PD1 during antigen presentation (Reuter et al., 2012). 
IFN-γ, though reported to have antiviral effects in the early stages of acute HIV infection, leads to 
an increased expression of apoptotic receptors and an increased expression of the enzyme 2, 3 
dyoxigenase (IDO) which catalytically breaks down tryptophan - an essential metabolite for T cells 
(Catalfamo et al., 2012). IL7 plays a role in T-cell homeostasis and may play a role in persistent 
activation of T-cells making them susceptible to HIV infection. Persistent immune activation is a 
predictive factor for persistent low-level viraemia (PLLV) observed in some patients receiving 
therapy (who have achieved viral load suppression below the detection limit of 20 -50 copies/ ml) 
(Catalfamo et al., 2012).  
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There are also bystander mechanisms that result in the killing of uninfected CD4+ T-cells. These 
include Caspase 3 and 1, TRAIL and FAS-mediated signalling pathways. The drop in the number 
of functional CD4+ T-cells occurs at an average rate of 16 cells per mm3 per month in non-treated 
patients (Tebas et al., 2002). Opportunistic infections that include tuberculosis, HIV-associated 
malignancies such as Kaposi sarcoma and dermatological diseases such as papular pruritic 
eruptions (PPE) are descriptive of the AIDS-defining symptom complex (Navarini et al., 2010) and 
are clinical markers of HIV-1 disease progression. 
1.2.3 HIV transmission routes 
HIV can spread horizontally via needle stick injuries, sexual intercourse and contact with 
contaminated blood fluids. It can also spread vertically via mother to child transmission (MTCT) 
(intra-uterine, prenatally or breastfeeding transmission), but heterosexual transmission, is the main 
mode of transmission and accounts for 85% of new infections worldwide (Simon et al., 2006). In 
industrialised countries, however, the main high-risk groups associated with HIV transmission are 
men who have sex with other men (MSM), Intravenous drug users (IDUs), and commercial sex 
workers.  
A recent meta-analysis of 39 studies spanning a period of about 4 years (2011 – 2015) on Sub-
Saharan Africa (Adetokunboh and Oluwasanu, 2015) showed that although cART has shown 
success in curbing HIV transmission rates HIV MTCT is still a major concern. HIV is genetically 
diverse and different subtypes may have different transmission efficiencies. For example, subtype 
A has been associated with a higher heterosexual transmission than subtype D but with MTCT, 
subtype C may be more transmissible than subtype A and D but however, less transmissible when 
compared to CRFs (Renjifo et al., 2004). 
Group M HIV-1 subtype C has emerged as the world’s most prevalent and dominant subtype and 
is responsible for approximately 48% of the world’s HIV-1 infections and an estimated 2 - 3 million 
new infections per year in the Sub-Saharan region (Hemelaar, 2013). However Sub-Saharan 
Africa, particularly Southern Africa, holds the highest HIV-1 subtype C prevalence and with more 
and more countries scaling up the roll out of ARVs, there is a growing concern for the management 
of patients and the monitoring of drug resistance (Hamers et al., 2012).   
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1.3 Antiretroviral therapy drug classes and mechanism of action 
Antiretroviral therapy has greatly changed the management of HIV infection globally and has led to 
the reduction of mortality and morbidity rates in many countries that have managed to successfully 
implement a national ARV rollout programme. Antiretroviral compounds used in therapy for long-
lasting viral suppression are classified into six different drug classes (Tang and Shafer, 2012). 
These classes include nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), non-
nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), entry inhibitors 
(fusion inhibitors and inhibitors of co-receptors) and integrase inhibitors (Table A). The 
classification system is derived from the viral life cycle step they inhibit, and each drug class has a 
specific mechanism of action. 
NRTIs limit HIV replication by acting as DNA chain terminators during reverse transcription of the 
HIV-1 RNA genome to complimentary DNA (cDNA). The pro-drugs (Table A) are first 
phosphorylated to active triphosphate forms that compete with the cells naturally produced dNTPs. 
Insertion of the active triphosphorylated forms of the drugs prevents the further incorporation of 
another dNTP molecule as the inhibitors lack a 3’ hydroxyl group that is essential for the formation 
of a phosphodiester bond during cDNA synthesis by HIV-1 RT enzyme (Das and Arnold, 2013). 
Nucleotide reverse transcriptase inhibitors are already mono-phosphorylated and require only two 
cellular phosphorylation steps. NNRTIs allosterically inhibit reverse transcriptase by binding to the 
hydrophobic region that is proximal to the RT active site (Jiao et al., 2011). The binding of the 
NNRTI molecule causes a conformational change in the catalytic core of the enzyme, inhibiting the 
release of the captured dNTP molecule by the enzyme. 
The same concept of enzyme competitive inhibition applies to protease inhibitors. Inhibitors of this 
class bind to the protease active site and this prevents the enzyme from accessing the gag and 
gag/pol polyprotein precursors that are catalysed by the enzyme to produce mature infectious viral 
particles (Tang and Shafer, 2012).  
Integrase strand transfer inhibitors (INSTIs) target the active site of HIV-1 Integrase and cause a 
conformational change in the enzyme that leads to the disruption of the correct positioning of the 
viral cDNA during strand transfer of the viral cDNA from the pre-integration complex to the open 
regions of the host chromosome (Xu and Kuritzkes, 2010). In addition to displacing the viral 
genome relative to the enzyme active site INSTIs also prevent interaction with magnesium ions 
required as cofactors for the Integrase enzyme. The strand transfer reaction is prevented, and this 
then blocks integration (Tang and Shafer, 2012).  
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Attachment and fusion inhibitors prevent viral entry: Inhibitors of CCR5 co-receptors allosterically 
bind to a pocket region of the host CCR5 co–receptor, changing its structure and inhibit HIV 
attachment by preventing the interaction of HIV-1 gp120 with CCR5. Binding of HIV-1 gp120 to the 
CCR5 receptor increases the proximity of HIV-1 gp41 to the host membrane to allow for 
subsequent fusion of the viral envelope and the host membrane; hence inhibitors targeting this 
step essentially prevent viral entry: After gp120 attachment HIV-1 gp41 gains access to the cell 
membrane and forms a hairpin by folding of its stalk. The shortened transmembrane protein brings 
the viral and cell membranes together promoting fusion of the two. In this regard, fusion inhibitors 
interfere with the hairpin formation of HIV-1 gp41, thereby preventing entry (Matos et al., 2010) that 
CCR5 inhibitors are only of benefit if the virus is CCR5 tropic and in cases where patients have 
CXCR4 or dual tropic viruses or a mixture of viruses with CCR5 and CXCR4 tropism CCR5 
inhibitors are not clinically useful. 
Table A – Summary of FDA approved ARVS 
Drug Class Integrase 
Inhibitors 
Entry Inhibitors Reverse Transcriptase Inhibitors Protease 
Inhibitors 
 
 
 
 
 
Single 
compound 
tablets 
 Fusion 
Inhibitor 
CCR5 
Antagonists 
Nucleoside 
(NRTI) 
Nucleotide 
(NRTI) 
Non-
nucleoside 
(NNRTI) 
 
Raltegravir 
Doltegravir 
Elvitegravir 
Enfuvirtide Maraviroc Abacavir (ABC) 
 
Tenofovir 
(TDF) 
Delviridine 
Efivarenz 
Nevaripine 
(Fos)Amprenavir 
Didanosine (ddI) 
 
Atazanavir 
Lamivudine 
(3TC) 
Darunavir 
 Indinavir 
Ritonavir 
Saquinavir 
Tripanavir 
Lopinavir/ 
ritonavir 
 
 
 
Fixed dose combinations 
Abacavir/Lamivudine (Epzicom)  
Zidovudine/Lamivune (Combivir) 
Tenofovir/Emtricitabine (Truvada) 
Abacavir/ Lamivudine/Zidovudine(Trizivir) 
Tenofovir/emtricitabine/ 
efivarenz (Atripla) 
Elvitegravir/cobicistat/Emtricitabine/Tenofovir 
(Stribilid) 
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1.3.1 HIV drug resistance mechanisms, evolution and viral fitness 
The high mutation rate of HIV-1 is an important biological factor contributing to HIV drug resistance. 
Approximately 1 - 3 mutations occur in each RNA genome target per round of replication (Mansky, 
1995). This is due to the error prone HIV-1 RT enzyme that lacks a 3’-> 5’ proofreading activity. 
Another contributing factor is that HIV-1 has a high recombination rate when co-infection of a cell 
occurs with more than one variant (Tang and Shafer, 2012). The high recombination rate is as a 
result of the mechanism (known as Copy choice) by which HIV-RT switches from one template to 
another during viral cDNA synthesis (Ramirez et al., 2008). 
HIV -1 replicates as a pool of diverse genomic sequences (known as quasispecies) containing both 
mutated and wild type strains. The quasispecies theory of molecular evolution describes HIV-1 
replication at viral population level (Perales et al., 2012). Replication proceeds under 
complementation and interference genomic interactions Complementation occurs when gene 
products necessary for the replication of a particular virus is provided by another viral genome 
whereas interference is when replication of one virus inhibits the replication of another strain (being 
the opposite of complementation). HIV-1 quasispecies interact by complementation and 
interference and the high diversity among replicating viruses also provide a genetic reservoir 
(termed quasispecies memory) (Perales et al., 2012).The genetic ‘reservoir’ allows replication-
competent DRVs first to emerge as drug-resistant minority strains and subsequently predominate 
as major variants if their genetic makeup provides a replication advantage in the presence of 
ARVs. The precise molecular mechanisms for drug resistance vary for each ARV class and the 
detailed discussion of drug resistance below is limited to NRTIs as the study focused on NRTI drug 
resistance and mutation fitness interactions. 
1.3.2 Molecular mechanisms of Nucleos(t)ide Reverse transcriptase resistance 
Molecular resistance with NRTIs is the result of the accumulation of mutations in HIV-1 pol gene 
(Johnson et al., 2003). These mutations can be classified as discriminatory or primer unblocking 
mutations based on the location within or near to the coding region of HIV-1 RT active site 
respectively (Tang and Shafer, 2012). 
Discriminatory mutations have been shown to have an effect on nucleoside incorporation, and 
common examples include K65R, M184V and Q151M. Discriminatory mutations derive their 
classification from the fact that their presence in HIV-1 RT enzyme enables the enzyme to 
differentiate better or discriminate the NRTI from the cell’s natural dNTPs, and this mechanism is a 
result of the alteration caused by the mutation on the conformation of HIV-1 RT active site (Curr et 
al., 2005; Garforth et al., 2007). 
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Discriminatory mutations such as M184V/I, K65R, L74V and Y115F located within the active site of 
the RT enzyme reduce viral fitness and range in their effect of causing intermediate to high-level 
clinical resistance to the NRTIs, which selects for them. For example, M184V causes high-level 
resistance to 3TC and FTC (Gotte, 2012) and low-level resistance to ABC and DDI but shows 
increased susceptibility to AZT and TDF (Tang and Shafer, 2012). Another example, K65R, which 
is selected by TDF and to some extent by ABC, D4T and ddI, shows intermediate resistance to all 
clinically approved NRTIs except AZT (Feng et al., 2005). The fact that these discriminatory 
mutations result in reduced fitness is an observation explained by the virus’s need to conserve 
energy at the molecular level during viral cDNA synthesis. This evolutionary mechanism suggests 
that reduced fitness is associated with increased replication fidelity and implies a decrease in the 
mutation rate of HIV-1(Dapp et al., 2012).  
Primer unblocking mutations (also known as thymidine analogue mutations – TAMs) have been 
shown to have an effect on ATP-mediated phosphorolytic excision of nucleosides (Richman, 
2006).TAMs are selected by thymidine analogues such as AZT and D4T, promote phosphorolytic 
excision of an NRTI that has been incorporated during chain elongation (Tang and Schafer, 2012). 
These mutations occur proximal to the RT active site coding area. This mechanism of 
phosphorolytic excision is based on the discovery that nucleotide incorporation by reverse 
transcriptase is a reversible process in the presence of ATP (Richman, 2006). Two evolutionary 
pathways have been described for the acquisition of TAMs: type I or type II (Shafer and Schapiro, 
2008). The type I TAMs include M41L, L210W, T215Y show increased high-level of resistance to 
TDF, ABC and ddI, whereas the type II TAMs, which include D67N, K70R, T215F, K219Q/E are 
described for intermediate resistance to AZT and D4T. The combination of TAMs and 
discriminatory mutations causes high-level resistance to almost all NRTIs (Martinez-Cajas and 
Wainberg, 2008).  
Two rare mutations associated with multiple NRTI drug resistance are insertions or deletions at 
codon 69 (known as T69ins/ T69del) and the Q151M (Johnson et al., 2003). The T69ins is known 
to co-occur with TAMs and causes high level clinical resistance to all NRTIs (Cases Gonzalez and 
Franco, 2007). The Q151M mutation is known to usually co-occur with accessory mutations that 
tend to promote the efficiency of the phosphorolytic excision reaction of NRTIs (Shirasaka et al., 
1995) and also known to be structurally located in HIV RT active site as the first amino acid in 
contact with a dNTP molecule and probably has an effect on dNTP insertion fidelity (Rezende et 
al., 1998). As part of the precursor of the multi-nucleoside resistance (MNR) complex that include 
accessory mutations F75I, F77L, F116Y and A62V, Q151M causes high-level clinical resistance to 
AZT, D4T, ddI and ABC and low – intermediate resistance to TDF, 3TC and FTC (Ueno et 
al.,1995).  
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Q151M and T69ins mutations are rarely observed to occur, but when they appear severely limit 
therapy options as they incur resistance to all NRTIs (Deval et al., 2002; Saini et al., 2012). 
1.3.3 Evolution of acquired antiretroviral resistance (therapy-induced) and transmitted 
antiretroviral drug resistance 
DRMs can be classified also as either arising from transmission of a drug resistant strain from one 
individual to another (transmitted drug resistance) or acquired (therapy- induced or secondary) 
resistance (Stott et al., 2012). Transmitted DRMs results from infection with a strain not fully 
susceptible to ARVs and varies in prevalence (from 5%-15%) depending on specific geographic 
locations (Jordan et al., 2012), whereas acquired resistance develops over time in patients 
receiving treatment and is due to selection pressures emanating from ARV use (Stott et al., 2012) 
DRMs can revert to wild type forms in untreated individuals over time (Kuritzkes, 2004) and this 
observation partially explains low prevalence rates observed before therapy initiation in many 
clinical settings. A random model of genetic bottlenecks has been postulated as a factor limiting 
the transmission of DRMs (Wagner et al., 2012). The model has a few assumptions which include: 
the probability of HIV-1 being transmitted in one single sex act as ranging from 0.001-0.003; time 
taken for reversion to occur for specific DRVs to wild-type forms ranging from 2 months – 8 years; 
and that reversion is due to the relative loss in fitness of the DRV compared to the wild-type. The 
smaller the fitness loss, the higher the probability that the variant will survive a genetic bottleneck 
and get transmitted and the more time needed for reversion to occur (Wagner et al., 2012). The 
dynamics of transmitted drug resistance remains complicated by a number of factors such as viral 
load, mode of transmission, level of adherence to ARVs and possible subtype differences which all 
could play a role in determining survival of DRVs exposed to genetic bottlenecks (Wagner et al., 
2012). 
The risk of acquired resistance in clinical practice is influenced by the genetic barrier of the ARVs 
used in treatment. A genetic barrier in the context of antiretroviral therapy refers to the number of 
mutations required to achieve resistance to any given ARV and ranges from low to high genetic 
barrier to resistance. For example, NNTRIs have a low genetic barrier as a single point mutation is 
sufficient to acquire high-level resistance to these drugs. PIs (when boosted with low dose 
ritonavir), in contrast, have high genetic barriers to resistance as three or more mutations are 
needed to acquire high level resistance (Tang and Shafer, 2012). The high genetic barrier of PI 
therapy as part of HAART contributed to the success of these regimens when introduced in 
patients who were therapy experienced as seen in a Swiss cohort study (Scherrer et al., 2012). 
The success of cART is also due to the different mechanisms of resistance to the different drug 
components.  
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The action of two or more drugs working in combination in suppressing viral replication decreases 
the probability of resistance-associated mutations (RAMs) being acquired by the virus to all drugs 
used in the treatment regimen (Rosenbloom et al., 2012). The observed patterns of acquired 
resistance have changed over time as a function of the change in recommended regimens 
according WHO guidelines (Van Zyl et al., 2013) and will likely continue to change as novel ARV 
drugs become available. 
1.3.4 Fitness and the role of secondary (compensatory or accessory) mutations in virus 
evolution 
Fitness is a relative measure of the replicative capacity of a given viral variant when compared to a 
wild-type strain (taken as a reference sequence) (Perales et al., 2012). In a particular study (Dapp 
et al., 2012), the relationship between fitness and replication fidelity was investigated. The study 
suggested a mutation rate close to HIV-1 wild-type strain represents the optimum for viral 
evolutionary adaptive forces. To add on, the study proposed a model that assumes that high 
replication fidelity implied evolution of HIV-1 to a lower mutation rate and factors such as changes 
in enzyme processivity and increased time for base recognition would require high energy 
demands that would inevitably result in a reduction of viral fitness. This could possibly explain why 
discriminatory mutations in HIV-1 pol gene result in less fit viral mutants (Tang and Shafer, 2012). 
However, the presence of secondary mutations in this gene, change enzyme kinetics in a way that 
overcomes the energy constraints needed for correct base incorporation during viral synthesis and 
this compensates for fitness loss (Dapp et al., 2012).  
Major NRTI mutations are known to decrease drug susceptibility of the virus at the expense of 
reduced viral fitness whereas the general accepted dogma for  secondary (accessory or 
compensatory) mutations is that these mutations maintain relative effect of decreased drug 
susceptibility imposed by major mutations but will enhance viral fitness (Xu and Kuritzkes, 2011) 
Secondary/compensatory mutations have been observed in some studies (Huang et al., 2011; Hu 
and Kuritzkes, 2011) playing a role in restoring viral fitness. Computer mathematical models have 
been developed to try and distinguish compensatory mutations from one another and to predict 
whether they have a role in viral fitness or drug resistance. Though controversial, one such model 
(Chen and Lee, 2006) takes into consideration the conditional parametric constant Ka/Ks, which is a 
measure of the selection pressure force on amino acid changes at one site in comparison to amino 
acid changes on another site. The conditional Ka/Ks gives a score to indicate negative selection 
(low score) or positive selection (high score) and was shown to be reproducible among four 
independent data sets and could efficiently be used to differentiate between primary and 
compensatory mutations. Its assumptions were argued to be reasonable given that HIV-1 is under 
strong selection pressure from both the immune system and ARV drugs.  
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Selection forces result in a high turnover of base transversions and transitions at the molecular 
level in the viral genome that gives the emergence of compensatory mutations that enable the 
virus to escape immune and drug neutralization while at the same time remaining fit (Quinones-
Mateu and Arts, 2002). 
1.4 Antiretroviral resistance and fitness testing and ex-vivo mutagenesis 
1.4.1 Antiretroviral resistance assays: genotypic and phenotypic drug resistance tests 
Antiretroviral drug resistance tests can be classified as genotypic and phenotypic tests (Stott et al., 
2012). Standard genotypic testing is done by performing PCR followed by standard DNA Sanger 
sequencing using primers that target relevant HIV-1 genes. Sequences obtained are analysed 
using either one of ten standard interpretation algorithms (five that are proprietary and five that are 
publicly available online) (Tang and Shafer, 2012). These interpretation algorithms compare the 
sample sequence to a wild-type strain (aligned to it as a reference) by first converting both 
genomic sequences to amino acid sequences and finding amino acid residues in the sample 
sequence that are different from the wild-type sequence. The amino acids that differ from the wild-
type are designated as mutations and are compared to a known list of clinically relevant DRMs 
before being reported to a specialist physician. Two commercial kits for HIV-1 genotypic testing 
and interpretation assays have been developed and these include the TRUGENE (Siemens, USA) 
and Celera ViroSeq® (Tang and Shafer, 2012). Genotypic assays have the following advantages 
over phenotypic tests: they are less expensive, are easier to perform, have short turnaround times, 
can detect evolving resistance in a presence of a mixture of viral genome sequences and can be 
used to quickly identify primary and compensatory mutations (Stott et al., 2012). However, they 
have the disadvantage of being less predictive of the effect of complex mutation combinations on 
drug resistance and viral fitness (Quinones-Mateu and Arts, 2002). To add on, the sensitivity of 
genotypic assays ranges from 100 – 1000 plasma HIV-1 RNA copies/ml and standard genotypic 
testing cannot detect DRVs below 20% of circulating virus population. However next generation 
sequencing technologies can detect minority drug-resistant variants as low as 1% of circulating 
virus population but their use is largely restricted to research settings only (Chang et al., 2013). 
Phenotypic tests detect DRMs by measuring viral replication of DRVs in cell culture assays in the 
presence of serial dilutions of the ARV drug. They are currently the gold standard for detecting the 
potency of novel ARV drugs and use two parametric measurements that determine cut off values 
for ARVs (Tang and Shafer, 2012). The cut-off values include the fold resistance cut off which is a 
measure of the minimal antiviral activity of the drug based on clinically relevant drug concentrations 
and the fold decrease in susceptibility based on IC50 values (inhibitory drug concentration required 
to suppress viral replication by 50%) (Tang and Shafer, 2012).  
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Phenotypic assays are more sensitive than standard genotypic assays in detecting minority drug-
resistant variants and in detecting fitness interactions of DRMs (Stott et al., 2012). 
Phenotypic assays are also used to accurately determine the tropism of viral variants. HIV-1, co-
receptor usage of patient viral quasispecies can be determined by amplifying the complete env 
gene, cloning the amplicons in mammalian expression vectors and transfecting the resultant 
plasmids in reporter cell lines expressing CCR5 of CXCR4 co-receptors. Though extensively used 
in research practices there are a few available commercial phenotypic assays to determine ARV 
potency and these include the PhenoSense (Virologic, Inc.) and AntiVirogram. The Trofile® 
Manogram is the commercial kit available to assess HIV-1 co-receptor usage (Tang and Shafer, 
2012).   
Phenotypic assays have a significant disadvantage in that many of the assays require extensive 
optimization for them to be validated in order to obtain results accurately (Weber et al., 2011). They 
are time consuming because of cloning steps that are essential in the synthesis of plasmid 
constructs before transfection in cell lines. They also require multiple controls for experimental 
validity and the plasmid constructs in turn should be quantified and assessed to display optimal 
fitness in cell culture (Quinones-Mateu and Arts, 2006). The assay setup also requires various 
optimisation steps before implementation in a laboratory.   
1.4.2 Fitness assays 
Assays for measuring viral fitness require reporter infectious plasmids to accurately measure viral 
replication in target cells. Examples of common reporter systems utilized in the study of HIV-1 
pathogenesis have plasmid constructs that use eGFP (enhanced green fluorescence protein), 
Luciferase or membrane-bound proteins such as HSA (Heat stable antigen) and PLAP(placental 
alkaline phosphatase) that are targeted by fluorescence–labelled antibodies for detection of 
infected cells (Imbeault et al., 2009). However, most HIV-1 reporter constructs, have the reporter 
systems mentioned above replacing accessory genes (nef, vpu or vpr) and even in env 
compromising the fitness status of the plasmid when transfected in primary or immortal cell lines 
(Imbeault et al., 2009). Viral fitness as a measure of the replicative capacity of a given viral isolate 
in a particular environment is hard to measure because of environment fluctuations and 
interactions of viral quasispecies that complicate its estimation (Quinones-Mateu and Arts, 2006). 
Various methods used for quantification of viral fitness (figure 2) have been developed and are 
classified into in-vivo or in vitro based assays. 
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Figure 2. Summary of HIV-1 fitness assays and their relative proportion as used in fitness studies 
(Picture adapted with permission (see Addendum A2) from Quinones-Mateu and Arts, 2002) 
In vivo based fitness assays (performed in model host organisms) assess HIV-1 kinetics in plasma 
(by PCR amplification and sequencing or differential hybridization techniques of extracted viral 
isolates from target cells). However, they present a challenge in that differences in host factors, 
host-pathogen interactions vary from individual to individual and viral fitness cannot be assumed to 
be constant in such scenarios (Quinones-Mateu and Arts, 2006). On the other hand, ex vivo/in vitro 
assays are independent of genetic differences between individuals and measure fitness on 
standardized systems. Ex vivo assays are categorised into mono-infection assays (where a single 
isolate is used to infect cell lines in a single round of replication or in SCID mice models or in viral 
growth kinetics) They are also classified as enzymatic assays that detect HIV-1 protease, RT 
activity (Malmsten, 2005) and growth competition assays (which assess co-infection of two or more 
viral isolates in cell lines and the proportion of each isolate in the mixture is determined after 
several viral passages. 
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Growth competition assays are the gold standard for measuring fitness as they model the in vivo 
quasispecies evolutionary dynamics more accurately (Picardo and Martinez, 2008). Various 
detection systems for growth competition systems have been developed and these include FACS-
based analysis (Brockmann et al., 2005); qPCR (Hoffmann et al., 2011); steady-state kinetic 
analyses measuring HIV p24 Antigen or RT activity (Van der Kuyl et al., 2010) and heteroduplex 
tracking assays that use fluorescence labelled specific probes that target a specific viral isolate 
(Van der Kuyl et al., 2010). A more sensitive variation for growth competition assays uses allele-
specific qPCR detection (Bergroth et al., 2005) and in such a format primers are specifically 
designed to detect point mutations with increased sensitivity and specificity. The major challenge 
with this format of the assay is that multiple primers would have to be designed to detect all 
relevant mutations of interest and that it will be labour intensive to perform head to head growth 
competition experiments of all mutant variants with the wild type. Regardless of the technical and 
labour-intensive challenges growth competition assays impose, they are still the main advantage 
over other assays and give a more accurate measure of fitness by direct comparison between the 
outgrowth of one viral isolate from another under constant and internally controlled conditions 
(Quinones-Mateu and Arts, 2002). 
The majority of studies, calculate fitness as a relative measure of the proportion of one isolate to 
another and the basic formula described by Holland and colleagues (Koval et al., 2006) given as:  
s = ln[(Mt /M0) /(Rt /R0)] /t, 
Where s is the fitness measurement value obtained when the natural logarithm of the ratio of Mt 
and M0 (mutant proportions at time t and time 0 respectively) to the ratio of Rt and R0 (reference 
strain/wild-type proportions at time t and time 0 respectively) are computed. 
The formula can also be extended by a number of variables that take into account the growth and 
death rate of isolates that are in comparison to each other (Miao et al., 2008; Ma et al., 2010).  
1.4.3 Ex vivo mutagenesis assays: Methods and research/clinical usefulness 
The technique of ex vivo mutagenesis/ site-directed mutagenesis can be used to assess whether a 
mutation can be considered to be clinically relevant to be adequately defined as a DRM. 
Site directed mutagenesis (SDM) allows the change of a nucleotide sequence to represent that of 
the desired mutant sequence thereby allowing evaluation of gene function in phenotypic assays 
(Wu et al., 2013). Methods employed in site directed mutagenesis include PCR and selection-
based methods. 
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PCR-based methods have many variations but the general method requires two sets of a pair of 
primers designed to introduce base substitutions, deletions or insertions at the target site of the 
sequence (Ho et al., 1989). In the first round of PCR amplification of the target sequence, each pair 
of primers generates amplicons that overlap each other at the mutagenic site 
The amplicons are then allowed to anneal to each other in a second round of PCR amplification 
generating a linear fragment that has the intended base modification(s) (Landt et al., 1990). The 
linear mutated fragment can be cloned into a suitable backbone vector and quantified in 
downstream experiments. Cloning of the fragment is dependent on unique restriction sites that are 
incorporated into the primers and are introduced in the resultant amplicon after successful rounds 
of PCR amplification.  
The same unique restriction sites can then be used to check for correct insertion of the mutated 
fragment via restriction enzyme digestion and gel electrophoresis analysis of the products of 
digestion. Standard DNA Sanger sequencing can then be used for verification of the insert, 
confirmation of desired mutations and additional checks to verify the absence of random undesired 
mutations that would have been generated by PCR (Ho et al., 1989). 
Selection based methods include the use of phosphorothioate-modified nucleotides that are 
treated in the desired sequence intended for base modification (preventing the sequence from 
restriction enzyme digestion and allowing selection from the untreated wild-type sequence) (Lui 
and Lomonossoff, 2006). Selection-based methods include ampicillin or tetracycline resistance 
genes that are expressed on plasmids subcloned with the mutagenic fragment but absent on wild-
type plasmids and are used for selection during cloning techniques (Jian et al., 1991). Finally, 
selection-based methods include deletion of unique restriction sites and dpnI treatment (Lui and 
Lomonossoff, 2006). DpnI treatment has become the most popular method for SDM and is 
commercialised in most SDM kits such as the Quick Change XL SDM kit (Stratagene, USA) and 
Q5™ mutagenesis kit (New England Biolabs (NEB), USA). The selection based method for DpnI 
treatment takes advantage of the property of methylation (Weiner et al., 1994). The wild-type 
plasmid is chemically transformed in dam+ bacterial competent cells that result in the methylation 
of the sequence. The wild-type methylated sequence is then used as a template for mutagenesis in 
a PCR that includes mutagenic primers overlapping at the target site for base modification. The 
products generated by PCR are linear and partially nicked unmethylated sequences. These can 
then be distinguished from the methylated wild-type using DpnI restriction enzyme that will catalyse 
the digestion of the methylated or hemimethylated sequence (Weiner et al., 1994). The partial nick 
in the mutant sequence is then rectified by the action of DNA ligase that is added to the post-PCR 
reaction or repaired by DNA repair systems (Goodman, 2012) of the competent bacterial cells 
upon subsequent transformation. 
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The use of SDM has been shown as an invaluable tool for the study of gene and protein function 
and in trying to establish the determinants of the mechanisms of various pathogens in causing 
diseases (Seyfang and Jin, 2003). Particularly, SDM assays in HIV-1 research have been used to 
identify critical determinants of gene function and structure and examples include RNase H studies 
(Mizrahi et al., 1990) HIV-1 RT enzyme studies (Garforth et al., 2007) and research on accessory 
proteins such as vpu (Nomaguchi et al., 2010).To add on, application of SDM assays in HIV-1 
research has been extensive in the classification of DRMs, fitness interactions and lethal 
mutagenesis (Dapp et al., 2013).  
By introducing various point mutations in the gene sequence of HIV-1 RT and subcloning the gene 
in an HIV-1 backbone vector, mutant derivatives synthesized can be used to determine the effect 
of a point mutation that affects drug resistance or viral fitness. 
More recent work utilizing SDM techniques on the A62V mutation, describe patients having this 
mutation experiencing failure on most of all the approved NRTIs except TDF. The A62V is part of 
both multi-nucleoside resistance complex (MNR) mutation pathways. Its biological role has been 
hypothesized to cause increased excision of NRTIs, when present in MNR complex containing 
insertions at position 69 of RT (Svarovskaia et al., 2008). Another report describes A62V to be 
associated with conformational changes in HIV 1 RT that causes it to shift between two states (pre-
translocational and post-translocational). The A62V mutation promotes the pre-translocational 
state that encourages the ATP or pyrophosphate mediated excision of NRTIs, which enables HIV-1 
RT to resume chain elongation (Scarth et al., 2011). 
1.4.4 Preliminary data for study 
Preliminary data (Figure 3) from a large laboratory-based dataset of HIV drug resistance 
comprising 164 patients (from Tygerberg Hospital, South Africa) on the TDF regimen involving 
either EFV or NVP as an NNRTI backbone, revealed that A62V occurred in ~36.6% of the total 
number of patients who had the K65R and M184V RT mutations, whereas the rate of co-
occurrence with M184V or K65R alone was low. From the observation, the exact role of A62V 
mutation is not entirely understood and whether it acts as a compensatory or accessory mutation is 
the primary focus of this study. 
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164 HIV-1 patients tested at Tygerberg Hospital on TDF/3TC or FTC/EFV or NVP 
 
Figure 3: Preliminary Data for study showing that A62V occurs more frequently (P<0.01 fisher 
exact test) with M184V and K65R.  
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Research Hypothesis and Aims 
This study is a descriptive experiment design study. 
The research hypothesis is as follows: 
HIV-1 RT A62V mutation has a compensatory role when it co-occurs with M184V and K65R 
in HIV-1 Subtype C, restoring viral fitness. 
The null hypothesis is: 
There is no significant change in viral fitness when A62V co-occurs with M184V and K65R 
HIV-1 RT mutations in HIV-1 Subtype C. 
The specific aim of the study is to design and optimize a phenotypic growth competition assay that 
will investigate this in HIV-1 Subtype C. This includes the following specific objectives: 
1. Synthesis of the following full-length genome (FLG) plasmid constructs harbouring these 
mutations:  
 A62V; 
 M184V, 
 K65R, 
 A62V+M184V, 
 K65R+ M184V; 
 A62V+ K65R, 
 A62V+K65R+M184V  
 
2. Testing the relative fitness of A62V+K65R+M184V vs M184V+K65R clones in a head to 
head in-house allele-specific quantitative PCR (qPCR)-based growth competition assay. 
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Chapter 2 - Materials and Methods 
Introduction 
This study’s aim was to test the hypothesis that A62V compensates for viral fitness loss, 
associated with M184V and K65R, when it co-occurs with M184V and K65R. The methodology 
used to approach the study objectives under this aim is described under three sections (Figure 4) 
with the third section being a result of the technical challenges encountered with the first two 
sections. The initial overall plan to synthesize full-length genome (FLG) mutant clones under the 
first two sections is given in Figure 5 whereas the alternative plan that employed different cloning 
methods is described in section 3 of the methodology for the study. A list of the major computer 
software, equipment, reagents and research kits mentioned in this chapter is presented in 
Addendum B. 
 
Figure 4. Overview of methodology plan for study 
Section1:  
PCR of HIV-1 RT gene 
Section 2: 
1.)Mutagenesis of RT gene 
2.) Synthesis of HIV-1C 
backbone vector 
Section 3:  
Alternative cloning plan 
using NL4.3 eGFP 
Section 3:  
1.)Growth competition 
experiment 
2) Allele-specific qPCR 
3) Result analysis 
Stellenbosch University  https://scholar.sun.ac.za
23 
 
 
Figure 5. Initial Overall cloning strategy derived from Section 1 and 2 methods. RT gene is 
amplified from TV1 (HIV-1C) sequence, mutated and subcloned into mini-plasmids (shown as 
circles) before being finally cloned in the TV1 HIV-1C backbone vector. Green ticks indicate 
successfully synthesized plasmids whereas red crosses do not. 
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2.1 Ethical considerations  
Ethical approval for the study was granted by the Health Research Committee of Stellenbosch 
University, South Africa on the 8th of April 2013 (ethics number N13/02/027) for one year and 
renewed for another year on the 14th of February 2014. 
2.2 Section 1- PCR of HIV-1C RT gene 
2.2.1-DNA amplification of HIV-1 gag-->start of end gene (HXB2 nucleotide positions 1683 → 
6189) 
A patient derived HIV-1 Subtype C full genome DNA viral sequence designated TV1 (Tygerberg 
Virology sample 1) was PCR amplified from the mid part of HIV-1 gag to the start of env (HXB2 
nucleotide positions 1683 → 6189 - Figure 6). PCR with the Go-Taq long-range PCR system 
(Promega, USA) yielded an amplicon that was approximately 4.5kb long (Addendum C1). The 
PCR reaction was validated with a 17.5kb β-globin fragment DNA positive control that is supplied 
with the kit. The optimized PCR protocol is given in Table B. 
 
AgeI forward primer      PacI reverse primer 
 
Figure 6. HIV-1 genome map showing positions of primers (AgeI forward primer and PacI reverse 
primer) that amplify the gag--> start of env gene (HXB2 nucleotide positions 1683 → 6189) 
Stellenbosch University  https://scholar.sun.ac.za
25 
 
Table B. Optimized protocol for PCR amplification of HIV-1C RT gene 
Go Taq_Long range PCR protocol 
Reagents Stock 
concentration 
Stock 
Volume 
Final 
concentration 
Volume(µl)/50µl 
Go Taq_Master Mix 2X 1.25ml 1X 25 
AgeI_forward primer 
(CTATGTAGACCGGTTCTTT) 
100nM 1.5ml 
(10µM) 
200nM – 300nM 3 
PacI reverse primer 
(CTCTAATTCTTTTAATTAACCA) 
100nM 1.5ml 
(10µM) 
200nM – 300nM 3 
Template DNA (TV1) variable variable 10ng 2 
Double Sterilized Water    17 
Total    50 
Go Taq_Long range PCR control     
Go Taq_Master Mix 2X 1.25ml 1X 25 
PCR master primer pair 10µM each primer 
pair 
  1 
Human genomic DNA (17.5 30µg  4ng 1/50 of Stock 
Nuclease free water to a final 
volume 
   50 
 
Thermal cycling conditions (Using the ABI Veriti thermal cycler – Applied Biosystems, CA, USA) 
were set as follows: initial denaturation at 94°C for 2 minutes for 1 cycle, 30 cycles of denaturation 
at 94°C for 15 seconds, annealing at 55°C /53°C /52 °C for 30 seconds and elongation at 68°C for 
5 minutes 5 sec and with 1 cycle for final elongation at 68°C for 7 min before chilling at 4°C. The 
correct size PCR product was visualised by gel electrophoresis using Novel Juice™ DNA stain 
(Promega, USA) and a 1 kb molecular weight marker(Promega, USA) with the remainder stored at 
-20°C for later use. 
2.2.2 Cloning of HIV-1 gag-->start of env gene (HXB2 nucleotide positions 1683 → 6189) 
Successful cloning of the HIV-1 pol amplicon was achieved via two sequential steps. The first step 
involved a clean-up of the PCR product using the MinElute enzyme reaction clean-up (Qiagen, 
Germany) following the manufacturer’s protocol (Addendum C2). The subsequent reaction 
involved restriction enzyme digestion at 37⁰C using 100units per reaction of BamHI restriction 
enzyme diluted in a final concentration of 1x NEB cutsmart  buffer(New England Biolabs, USA) in a 
final volume of 50 µl. The reaction yielded two fragments of size 2kb and 2.5kb respectively which 
were again purified using the mini elute clean-up reaction from Qiagen. 
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The 2kb fragment covered the central part of gag to the mid part of pol (HXB2 nucleotide positions 
1683→3776) and the 2.5kb fragment covered the mid of pol to the start of env (HXB2 nucleotide 
positions 3776→ 6189). The second step involved separate ligation of the two individual fragments 
using T4 DNA ligation system (Promega, USA) into p- GEM T easy vector (Promega, USA). The p- 
GEM T easy 3015bp vector contains an ampicillin resistant gene. The vector also has an essential 
feature that can be used to discriminate between desired bacterial colonies that contain the 
required plasmids and undesired colonies after successful transformation. This feature is a multiple 
cloning region that overlaps with the β-galactosidase enzyme gene (LacZ) contained in the vector. 
Cloning a fragment in the multiple cloning site results in the disruption of the LacZ gene and hence 
bacterial cells that incorporate this plasmid after chemical transformation generate white colonies 
when plated out on LB agar ampicillin plates, containing X-gal and IPTG. Bacterial cells that 
incorporate a plasmid with a functional LacZ gene (specifically if self-ligation of the vector occurred 
and no fragment has been integrated into the multiple cloning site) appear with a blue phenotype. 
The blue colour is indicative of the catabolism of the X-gal substrate by the expressed β-
galactosidase enzyme and hence colonies that show this phenotype are undesired colonies.  The 
ligation reaction conditions in this study using p-GEM T-easy vector, were optimized following the 
manufacturer’s recommendations (see Addendum D1 for specific reaction conditions and 
Addendum D2 for the plasmid maps of the cloned fragments designated TV1-2kb and Tv1 2.5kb 
plasmids respectively).  
For chemical transformation, 5µl of each ligation reaction for TV1-2kb and TV1-2.5kb to p-GEM T 
easy vector was added to 50µl of JM109 (Promega, USA) E. coli competent cells in a propylene 
Eppendorf tube and incubated on ice for 30 minutes before being chemically transformed by heat 
shock at exactly 42°C. The heat shock step activates calcium-gated channels within the bacterial 
membrane pores, which open up to allow plasmid DNA uptake into the bacterial cytoplasm. The 
calcium-gated channels are regulated by the concentration difference of calcium ions inside and 
outside the bacterial cell. After the heat shock step, reactions were further incubated on ice for 2 
minutes before 900µl of S.O.C medium was added and after that the reactions were transferred to 
a shaker incubator (Labcon, USA) for incubation at 37°C and shaking at 225 rpm for 1hr. After the 
incubation step, bacteria from 100µl of each reaction tube were spread on prepared Lb agar 
ampicillin plates containing X-gal and IPTG. These plates were incubated overnight at 37°C, and 
white colonies were selected from the agar plates the following day. Each white bacterial colony 
that was expected to represent the successfully cloned fragments were cultured in 5ml of 1 x LB 
media and incubated for 16hrs in a shaker incubator (Labcon, USA) at 37⁰C and shaking at 
185rpm to generate Miniprep DNA. 
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Miniprep DNA was prepared from bacterial cultures using the Promega Miniprep Kit (Promega, 
USA) and DNA plasmids obtained were quantified on the NanoDrop™ ND 1000 
Spectrophotometer (ThermoScientific, USA) before subsequent DNA Sanger sequencing using the 
Big dye cycle sequencing kit v3.1 (Applied Biosystems, CA, USA). Fragments generated from the 
sequencing PCR reaction were then read on the ABI 3130xL Genetic Analyser. Primers for 
sequencing inserts, including the standard vector sequencing primers (M13 forward and M13 
reverse) and are shown in Table C. The primers were designed using the open source 
bioinformatics program UGENE (Unipro, Novosibirsk, Russia) and were used at a final 
concentration of 200nmol for the sequencing reaction following the manufacturer’s sequencing 
protocol that was optimized for plasmid miniprep sequencing (Addendum E) for the sequencing 
PCR reaction. 
 
Table C. Sequencing primers for tv1-2kb and tv1-2.5kb inserts 
Sequencing primers for tv1-2kb and tv1-2.5kb inserts 
Tv1_2.5kb primers (5’-3’ direction) Tv1-2kb primers (5’-3’) direction 
 p1 AAGAGCAAGAAATGGAGCCA p10_compliment GAACCCCCATTTCTTTGGAT 
p3 AGGAATTGGGGGAAATGAAC p11 AGTGCTAGATGTGGGGGATG 
p3 compliment TTAGCAGGAAGATGGCCAGT p11_compliment AAGAACCCCCATTTCTTTGG 
p7 GCATTTGGGTCATGGAGTCT 2p4 AAAGGGCTGTTGGAAATGTG 
p7_compliment TCAAGCAGGAAGCTGTCAGA 2p4_compliment ATGATAGGGGGAATTGGAGG 
p1.1 CCCTACAATCCCCAAAGTC 2p7 GGGCCTACACCAGTCAACAT 
p1.1_compliment GACCAGCCGAACTACTCTGG 2p7_compliment AGGAATACCACACCCAGCAG 
M13 Forward Primer - GTAAAACGACGGCCAGT 
M13 Reverse Primer - GTTTTCCCAGTCACGAC 
 
Plasmid integrity was further confirmed by restriction enzyme digestion as shown in Figure 7 
following the NEB restriction enzyme digestion protocol (Addendum F). 
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Figure 7. Restriction enzyme digestion to confirm insertion of pol fragments in p- Gem T easy 
vector. ‘M’ is the 1kb molecular marker (Promega, USA). Band fragments correspond to the size 
fragment expected when digested with restriction enzymes for TV1-2kb and TV1-2.5kb which are 
AgeI + BamHI and PacI + BamHI, respectively, as shown on the gel photo. 
 
2.3 Section 2 –Site-directed mutagenesis, HIV-1 subtype C vector backbone construction 
and cell culture 
2.3.1 Site-Directed Mutagenesis (SDM) 
The TV1-2kb plasmid was the plasmid of choice to introduce mutations of interest as the insert 
from this plasmid contains the whole coding region of RT enzyme. The mutations A62V, K65R and 
M184V, were introduced in this clone by using the following methods for site-directed mutagenesis:  
1) Direct mutagenesis of plasmid using the property of DNA methylation to differentiate wild-type 
clones from mutant clones 
2) Overlap extension PCR method (Ho et al., 1989).  
In this study, direct mutagenesis of the TV1-2kb plasmids was done using the Quick Change II XL 
Site-directed mutagenesis kit (Stratagene, USA). SDM primers for this method were designed 
using the mutagenesis primer tool from Stratagene’s website 
(http://www.Genomics.agilent.com/primer DesignProgram.jsp) and are indicated in Table D 
section A overleaf.   
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The reaction conditions for amplification (Using the ABI Veriti thermal cycler – Applied Biosystems, 
CA, USA) of the plasmid for mutagenesis were followed according to the manufacturer’s protocol 
and these are: a single cycle of initial denaturation at 95⁰C for 1min, 18 cycles of denaturation at 
95⁰C for 50 sec, annealing at 57⁰C/62 ⁰C/63⁰C/65⁰C ( being primer specific) for 50 sec and 
elongation at 68⁰C for 5min 10 sec and a final elongation cycle of 68⁰C for 7 minutes before 
chilling at 4⁰C.  
Afterwards, the PCR product obtained was further incubated on ice for 2min before subsequent 
treatment with dpnI enzyme at 37⁰C for 1hr to digest methylated and hemi-methylated wild type 
sequences. 
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The digested product was subsequently transformed into XL1 super competent cells and mutant 
colonies were distinguished from non-mutant colonies by downstream DNA Sanger sequencing. 
Normal screening with X-gal chemistry could not be applied as these were sub-clones that already 
had the β- galactosidase gene disrupted upon insertion of the TV1-2kb fragment. Hence, white 
colonies were expected. Optimization of this method proved technically challenging and time-
consuming; and only the M184V mutant subclone construct was successfully synthesized. Five of 
the remaining six mutant constructs needed for the study were synthesized using the overlap 
extension PCR method described in the following section.   
2.3.2 Site-directed mutagenesis by Overlap extension using PCR - method principle and 
application: 
The method was first described by Ho et al., 1989 and uses two sets two of anti-parallel primers for 
mutagenesis. In each set of primers, one of the primers contains the base mismatch(es) that will 
be directed to the target sequence. This primer is overlapping with the complementary primer of 
the other set, while the other primer of the set contains a restriction enzyme target sequence. The 
amplicons generated by each of the two primer sets are used in a subsequent second PCR 
reaction as primers against each other. This second round PCR reaction is conditioned by the fact 
that the amplicons overlap each other by at least 15bp upstream the 3’ end of each amplicon. The 
resultant dsDNA fragment that is synthesized from the 2ND PCR reaction contains the mutation of 
interest and restriction enzyme sequences that are incorporated at the 3’ and 5’ end of the 
fragment. The fragment is subsequently, digested with the appropriate enzymes to allow re-ligation 
into the original vector. The presence of mutations are confirmed with DNA Sanger sequencing. 
In this study, two sets of primers were designed to generate a fragment that contains the mutations 
of interest for the project using the overlap extension by PCR mutagenesis method. The primers 
listed in TABLE D section B for this method yielded the expected fragments for both rounds of 
PCR (Addendum G1) using the Expand Hi-fidelity PCR System (Roche Diagnostics, Switzerland) 
following the manufacturer's guidelines and protocol for PCR amplification (Addendum G2).  
Calculations for annealing temperatures of the primers for the first round of PCR were done using 
the formula adapted from the National Forensic Science Technology Center  (NFSTC, USA- 
http://www.nfstc.org/pdi/Subject04/pdi_s04_m01_02_c.htm) below: 
𝑇𝑎𝑂𝑝𝑡 = 0.3(𝑇𝑚𝑃1) + 0.7(𝑇𝑚𝑃2) − 25°𝐶, 
 Where 𝑇𝑎𝑂𝑝𝑡 is the desired optimal annealing temperature and  𝑇𝑚𝑃1  and 𝑇𝑚𝑃2 are melting 
temperatures of primers 1 and 2 respectively. 
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The second round used a constant annealing temperature of 55°C and resultant fragments were 
synthesized by the pair of the first round amplicons representing each mutant construct (Table E). 
To complete the first objective of the project three other mutant constructs were synthesized by 
recombination of the fragments (Table E section A) generated in the 2nd PCR round via 
compatible restriction sites with the M184V mutant construct synthesized by Quick Change XL 
SDM kit.  
Table E. Summary of SDM overlap extension PCR generated amplicons 
Mutant Construct Combinations of Amplicons from 
1
st
 PCR rnd 
Restriction enzymes to be used 
A62V + K65R HK + AK AvrII + HindIII 
A62V HA + AA AvrII + HindIII 
K65R H5 + A5 AvrII + HindIII 
M184V PM +AM  HindIII + PasI or AvrII + PasI 
   
Section A 
Other constructs Fragment(from 2
nd
 PCR rnd) 
ligated to M184V sub-clone 
Construct 
Restriction enzymes to be used 
A62V + M184V (HA + AA) AvrII + HindIII 
M184V + K65R (H5 + A5) AvrII + HindIII 
A62V + M184V + K65R (HK + AK) AvrII + HindIII 
 
2.4 HIV-1 subtype C backbone vector construction  
The plan for synthesis used two source clones that had the 5’ LTR – pol end (HXB2 nucleotide 
positions 1 → 6186) and pol end – 3’LTR (HXB2 nucleotide positions 6223 → 8795) inserts of the 
consensus TV1 HIV-1 full genome sequence (Genbank ascension number AY162223). The clones 
designated in this study as TV1- S-clone and MJ4/TV1 hybrid for the 5’ LTR – pol end and pol 
end – 3’LTR of HIV-1 respectively, (shown in Figure 8A and 8B) were each digested with the 
restriction enzymes PacI and NgoMIV, following the NEB digest protocol (Addendum F). The 
desired fragments after digestion were size-selected using gel electrophoresis and after that, gel 
extracted using the QiaxII gel extraction kit (Qiagen, Germany). The gel-extracted fragments were 
ligated using T4 DNA ligase system (Promega, USA) and transformed into Stable 2 E. coli 
competent cells (Invitrogen, USA).
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Colonies were picked from agar plates after successful transformation and were then inoculated in 
5ml of 1x LB media for miniprep DNA following the procedure and protocol described in the 
previous sections. Positive miniprep DNA samples were confirmed by restriction enzyme digestion 
and sequencing. Plasmid maps and simulations for ligation, cloning and digestion reactions were 
done using the SnapGene software program (GSL Biotech, USA). 
 
Figure 8A – Tv1- S-clone with desired fragment for full-length genome synthesis being the feature 
labelled and highlighted in grey. Restriction sites PacI and NgoMIV are shown marked in black. 
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Figure 8B – MJ4/TV1 hybrid labelled clone with the desired fragment for full-length genome 
synthesis highlighted in green. Restriction sites PacI and NgoMIV are shown marked in black. 
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The full-length HIV-1 subtype C construct (TV1-FLG) cloned in the p-Blue script vector after 
ligation of the two fragments is shown in Addendum H with the essential features marked. Ligation 
of these fragments was successfully achieved by extending the incubation time for ligation to 48hrs 
at 4°C to promote efficient circularization. Maxiprep stocks were prepared for TV1-FLG using the 
Pure Yield Maxi prep Kit (Promega, USA) and quantified spectrophotometrically by the 
NanoDrop™ 1000 (ThermoScientific, USA) before being stored at -20°C for subsequent use in cell 
culture assays. The average concentration of DNA plasmid obtained was 500ng/µl 
2.5 Cell culture to test infectivity of TV1-FLG 
2.5.1 Seeding cells and transfection 
Infectivity of TV1-FLG was tested by infecting 293T and TZM-bl cells with viral supernatant 
obtained by the initial transfection of 293T cells and then measuring viral expression and infectivity 
of 293T and TZM-bl cells using standard HIV p24 ELISA and X-gal staining assays respectively. 
Before infection, 293T and TZM-bl cells were seeded at a concentration of 2 x 106 cells in T75cm2 
cell culture flasks and were grown until they achieved a 70 - 80% monolayer. Cells were initially 
cultured with growth media formulated with 10% (v/v) of fetal calf serum (FCS), DMEM (Dulbecco’s 
minimum essential medium) (Sigma-Aldrich, USA) and a cocktail of antibiotics (containing penicillin 
and streptomycin- Sigma-Aldrich, USA) before being refreshed every 2 days with maintenance 
media which had the same formulation as the growth media with an alteration of the FCS used 
(which was reduced to 5% (v/v)). For subculturing, cells were trypsinized using a 1:10 dilution of 
ATV solution (Sigma-Aldrich, USA) and then centrifuged at 900rpm for 7 minutes at room 
temperature. Afterwards, the supernatant was discarded before the cells were resuspended in 
growth media.  
A trypan blue exclusion assay was done to determine the number of viable cells, which were then 
counted by a TC20 automated cell counter (Bio-Rad, USA). 10µl of the suspended sample was 
taken and mixed (1:1) with 10µl of trypan blue solution (Bio-Rad, USA) before being added to a 
slide that the machine could read. The trypan dye solution can penetrate cells only if their cell 
membranes are disrupted indicating that the cell is non-viable. Figure 9 shows the gating strategy 
used on the TC20 automated counter to select the desirable cell size for 293T and TZM-bl cells for 
sub-culturing.  
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Figure 9. Image was taken from the TC20 automated cell counter showing the concentration of 
viable cells and the gating strategy used (setting the lower gate at 12µm – higher gate at 18µm) to 
allow the selection of mature and functional cells based on diameter cell size. 
The X-treme gene HD transfection reagent (Roche Diagnostics, Switzerland) was used to 
incorporate 2-5µg of plasmid DNA in 293T cells following the manufacturer’s protocol.  The 
protocol followed, was done in a BSL3 (Biosafety Level 3 access lab in the Division of Medical 
Virology, Stellenbosch University) under a biosafety class II cabinet without need for optimization 
and required that the 293T cells be seeded a day before transfection in 6 well culture plates at a 
concentration of 5 x 105 cells per well and incubated at 37°C with a constant 5% CO2 level  in a 
CO2 incubator (Nuaire, USA). After successful transfection of 293T cells, viral supernatant was 
then harvested after three days, centrifuged at 1200 rpm for 10 minutes at room temperature and 
the supernatant obtained was either cryopreserved at -20°C or -80⁰C or directly used to infect 
TZM-bl cells. The TZM-bl cells trypsinized from maintained cultures were seeded in a 96 well plate 
at a concentration of 1 x 105 cells per well a day before they were infected with 100µl of viral 
supernatant.  The viral supernatant derived from the transfection of 293T cells included TV1-FLG 
and control plasmids MJ4/TV1 subtype C hybrid plasmid (Jacobs et al., unpublished data), pZAC 
subtype C plasmid (Jacobs et al., 2012) and NL4.3 subtype B plasmid (AIDS Reagent Program, 
NIH, USA). The viral inoculums were stored -20°C or -80⁰C or directly used to infect TZM-bl cells 
for the X-gal staining/ B- galactosidase assay.  
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2.5.2 Cell culture end point assays to check infectivity of TV1_FLG 
HIV p24 ELISA assay 
The QuickTiter TM HIV Lentivirus Quantification kit (Cell Biolabs, Inc., San Diego USA) was used to 
measure gag p24 expression of HIV-1 in infected 293T cells: Anti-HIV p24 monoclonal coating 
antibody adsorbed onto a microtiter plate captures p24 antigen present in the sample.  
 FITC-conjugated mouse anti-p24 antibody is added to the sample to bind p24 antigen captured by 
the first antibody. After several incubation and wash steps, a HRP-conjugated mouse anti-FITC 
antibody is added and binds to the FITC conjugated anti-p24. The unbound HRP-conjugated 
mouse anti-FITC antibody is removed in a final wash step that is followed by addition of a substrate 
solution reactive with HRP which results in the formation of a chromogenic product that correlates 
with the amount of p24 antigen present in the. The reaction is then terminated by addition of acid 
and absorbance is measured at 450 nm using an ELISA plate reader. A standard curve prepared 
from recombinant HIV-1 p24 protein standards is used to determine the concentration of the 
sample. In this study, eight recombinant p24 standards were generated from the QuickTiter TM HIV 
Lentivirus Quantification kit and used to determine the concentration ofHIV-1 gag p24 expression 
in infected 293T cells. 
The assay was set up with NL4.3 viral supernatant being added to wells as a positive control and 
supernatant from pure cultures being added to wells as negative controls in a 96 well p24 
monoclonal antibody coated microtiter plate. TV1-FLG and MJ4/TV1 viral supernatant were also 
added, and the assay was then run following the manufacturer’s guidelines with each sample 
including standards being added in duplicate on the microtiter plate. Blank controls for 
normalization with the ELx800TM ELISA plate reader (Bio-Tek, USA) were also included to allow 
standardisation and accurate spectrophotometric readings of test samples. The ELx800 ELISA 
plate reader was configured for a system self-test to check whether the filters for the different 
absorbance wavelengths were functional before running the assay. The assay was only run after 
confirmation of a system test pass. 
HIV-1 X-gal Staining assay 
The TZM-bl cells plasmid (AIDS Reagent Program, National Institute of Health (NIH), USA) used in 
this study are a HeLa-derived cell line expressing CD4, CCR5 and CXCR4. The cells contain 
Luciferase and ß-galactosidase genes cloned in-frame and downstream the HIV LTR unit (Derdeyn 
et al., 2000).Upon being infected with HIV-1 virus particles the HIV-1 tat accessory protein can bind 
to the LTR unit which induces Luciferase and ß-galactosidase genes downstream expression in 
these cells and can be used as a marker to show infection with HIV-1.   
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In this study, determination of viral infectivity of TV1-FLG was done by analysing the expression of 
ß-galactosidase in TZM-bl cells using X-gal staining solution. 100µl of serially diluted stocks of 
TV1-FLG, MJ4/TV1, pZAC and NL4.3 were added to individual wells seeded with TZM-bl cells in 
triplicate on a 96 well culture plate and the plate was then incubated at 37°C with a constant 5% 
CO2 level in a CO2 incubator (Nuaire, USA) for 48hrs.  
Afterwards, the cells were fixed with a solution of methanol and acetone (1:1) for 5 minutes, 
washed 3 times with PBS and stained with 100 µl of X-gal staining buffer(Table F) per well which 
had the following formulation for a total volume of 5ml: 
Table F: Xgal staining buffer formulation 
Reagents Volumes required 
Xgal (50mg/ml in DMF- dimethyl fomamide)(Promega, 
USA) 
100 µl 
100mM MgCl2 (Sigma-Aldrich)  50 µl 
100 mM potassium ferricyanide (K3[Fe(CN)6]) (Sigma-
Aldrich) 
250 µl 
100mM potassium ferrocyanide (K4[Fe(CN)6]) (Sigma-
Aldrich) 
250 µl 
1xPhosphate buffer solution (PBS)(Lonza, 
Switzerland) 
4.35ml 
Total 5ml 
 
The stained plate was incubated for 24hrs, and image results of stained cells were captured using 
a light microscope after washing the plate with 1x PBS and damp drying on a lab sterile tissue 
towel. 
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2.6 Section 3 –Alternative backbone to assess mutations in HIV-1 subtype B reporter 
Plasmid 
The difficulties in constructing a pure HIV-1 infectious subtype C infectious clone led to a 
contingency plan to analyse the mutations of interest by ligation of the HIV-1 subtype C  reverse 
transcriptase fragment into the lab adapted NL4.3 eGFP (enhanced green fluorescent protein) 
subtype B reporter plasmid (Aids Reagent Program, NIH, USA). The plasmid has the eGFP gene 
cloned in-frame in the region where the nef gene of HIV-1 has been deleted. Expression of the 
eGFP gene in cell cultures can be used as a marker to quantify infected cells in downstream 
assays such as FACS based assay or for qualitative assessment using fluorescence microscopy. 
The methods described in the following sub–sections include efficient methods for cloning and 
mutagenesis of the desired constructs required by the first objective of this study and the design 
and optimization of the allele-specific qPCR assay used for the growth competition experiment 
specifically involving the A62V+K65R+M184V and K65R+M184V viruses to determine whether 
A62V compensates for K65R and M184V associated fitness loss.  
2.6.1 Synthesis of recombinant constructs using the infusion™ cloning method 
The preferred cloning method employed in this section was developed by Clontech, USA and is 
termed Infusion™ cloning. The basic components required for the cloning reaction include a PCR 
product (desired insert) that has been amplified by infusion primers, a suitable vector, Clontech’s 
proprietary Infusion HD cloning enzyme master mix and bacterial competent cells. The infusion 
primers are custom designed to have 15bp ends that are homologues to the ends of a suitable 
vector such that when used to amplify the desired insert, result in a PCR product with 15bp 
homologous ends to the vector. The vector itself is prepared by either restriction enzyme digestion 
(exposing overhangs with 15bp homology to the Insert) or PCR amplified with infusion primers 
partially complementary to the vector that result in the vector having the same 15bp homology with 
the Insert. The prepared insert and vector are then fused together in a ligation-independent 
reaction that includes the Infusion cloning HD enzyme master mix and is incubated at 50°C for 15-
30 minutes resulting in a circularized plasmid ready for transformation in bacterial competent cells. 
In this study, the vector was prepared from NL4.3 eGFP plasmid that was digested using the ApaI 
and AgeI restriction enzymes and the overall plan incorporating infusion cloning is shown in figure 
10. The insert was derived from MJ4 HIV -1 subtype C plasmid. The region amplified was the gag- 
pol region corresponding to ApaI- AgeI restriction sites in NL4.3 eGFP (HXB2 nucleotide positions 
2010 -3493). The infusion primers used to amplify the MJ4 are indicated in Table G and the 15bp 
homologous ends are color-coded in red.  
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Figure 10. Overall plan for Infusion cloning using NL4.3eGFP and the PCR insert derived from the 
MJ4 subtype C clone. Steps A and B are executed in parallel to obtain fragments at step E and D 
respectively. The fragments at E and D are the fused using Infusion cloning to give the product at 
step F
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Table G: - Infusion cloning primers 
Infusion primers for Insert Primer Sequence 
Forward primer(Infusion_online_tru_for) AAAAATTGCAGGGCCCCCTAGGAAAAAGGGCTG 
Reverse primer(Infusion_online_tru_rev) CACTCCATGTACCGGTGTACTGGTTCTTTTAGAATTT 
 
The complete workflow for the cloning plan was initiated by amplification of the MJ4 insert using 
the Q5™ hot start Hi-fidelity PCR protocol (NEB, USA) and the forward and reverse infusion 
primers for the MJ4 gag_pol region. The resultant PCR product (~1505bp) was cleaned up using 
the MiniElute clean-up kit (Qiagen, Germany). The clean-up reaction was done in parallel with the 
digestion of NL4.3 eGFP with ApaI and AgeI restriction enzymes following the restriction enzyme 
digest protocol from NEB (Addendum F). The linearized vector was gel extracted and purified 
using the QiaxII Gel extraction kit (Qiagen, Germany). The vector and PCR product were then 
quantified on the NanoDrop™ ND 1000 spectrophotometer and confirmed for DNA purity as well 
as the optimal concentration required for the Infusion cloning reaction. The optimized protocol for 
the infusion cloning reaction that resulted in an HIV-1 BC full-length genome (FLG) recombinant 
clone (~14.7kb) is indicated below in Table H 
Table H: - Infusion™ cloning reaction protocol 
Reaction Component Reaction 
Vector(203ng/µl)_Linearized NL4.3 eGFP 2µl 
Insert(46ng/µl)_ MJ4 gag-pol 3µl 
HD enzyme mix 2µl 
dd𝐻2O 3µl 
Total Volume 10µl 
Time of incubation @50°C 15 min 
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SDM using overlap extension PCR described in Section 2.3.1 was used to mutate the MJ4 Insert 
to generate mutated fragments containing A62V, K65R, M184V and their different combinations 
yielding seven mutated fragments in total. However, these fragments proved to be technically 
challenging to clone using the Infusion™ cloning method because of the resultant DNA yield 
obtained when the SDM protocol was applied. The yield proved to be insufficient to use in the 
infusion cloning reaction. An alternative strategy was used an optimized protocol adopted from 
Q5™ Mutagenesis protocol (NEB, USA) was then used to introduce mutations in the wild-type 
recombinant clone that had been successfully cloned by the infusion cloning technique. 
2.6.2 Synthesis of mutants by Q5™ Mutagenesis protocol 
The Q5™ Mutagenesis protocol (NEB, USA) is based on the SDM technique described previously 
in section 2.3.2 which uses discrimination of the wild-type and mutated constructs by dpnI 
digestion of methylated or hemi-methylated products that remain after PCR amplification of the 
wild-type template with mutagenic primers. Briefly, for the Q5™ mutagenesis protocol, the protocol 
is modified in a way to combine the ligation and dpnI enzymatic treatment in 1 step efficiently. 
Ligation in the reaction is first achieved by two mechanisms which include phosphorylation of the 
linear amplified PCR products by the action of a kinase enzyme followed by subsequent ligation of 
the phosphorylated ends by DNA ligase. The result after this process are circularized plasmids that 
are then discriminated for selection by dpnI enzyme, which in its mechanism of action will target 
the wild type methylated and hemi-methylated plasmids leaving the desired mutated constructs. 
The entire process that includes phosphorylation by the kinase enzyme, ligation by DNA ligase 
and digestion by dpnI is referred to as the KLD reaction (NEB, USA). After PCR amplification with 
the mutagenic primers, followed by the KLD reaction, samples are then transformed into bacterial 
competent cells and colonies obtained can be selected based on their ability to grow on antibiotic 
resistance plates. These colonies are indicative of successful transformation with plasmids that 
carry antibiotic resistance genes. The plasmids are then verified using standard DNA sequencing 
for integrity and to check for incorporation of desired mutations.  
In this study, Q5™ mutagenesis protocol was successfully used to mutate RT gene in the 14.7kb 
HIV-1 BC  FLG recombinant clone obtained by infusion™ cloning. Reverse and forward mutagenic 
primers were designed using the Snapgene program (GSL Biotech, USA). The primers are 
indicated in Table I, and the names designated for the primers are parenthesized below the primer 
sequence, with the mutagenic bases indicated in small cap letters. Primers were designed in a way 
to introduce substitution mutations (according to guidelines supplied by NEB in the Q5™ 
mutagenesis protocol) to synthesis A62V, K65R, M184V, A62V+K65R, A62V+M184V+K65R, 
K65R+M184V and A62V+M184V FLG constructs. 
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The manufacturer specifies that the protocol is designed to mutate fragments up to 14.3kb in 
length; however I modified the protocol by replacing the Q5™ hot start enzyme master mix used 
for PCR amplification and used Clontech’s Hi Fi PCR master mix and this resulted in an improved 
PCR efficiency of the wild- type recombinant clone. The KLD reaction components were used 
unmodified but the resultant mutated constructs were then transformed in JM109 mix and go 
competent cells (Zymo Research, CA, USA) which were competent cells observed to be valuable 
in shortening the time for the transformation reaction(~ 1min) compared with ~2hrs using the NEB 
5- alpha competent cells. 
Table I: - Q5™ mutagenesis primers 
 
The 14.7kb FLG constructs derived were verified by standard Sanger DNA sequencing using 
primers whose names and sequences are AK10 (TYCCCACTAAYTTCTGTATRTC) and 
AK11(GTACCAGTAAAATTAAARCCAG) following the Big dye cycle sequencing kit v3.1 (Applied 
Biosystems) optimized protocol (Addendum E). Once the constructs were obtained a maxi prep 
stock was made for each plasmid construct using the Maxiprep kit (Promega, USA) and stored in 
200µl constructs with an average concentration of 400ng/µl. 
Q5™ Mutagenesis designed primers 
Target  
Mutation 
Plasmid 
template for 
PCR 
amplification 
Forward Primer Reverse Primer 
A62V Wild type 
recombinant 
clone 
CTCCAGTATTTGtAATAAAAAAGAAAGACAGTAC 
(A_4wd) 
TATTATATGGATTTTCAGGCCCAATTTTTG 
(Q5_mut_rev) 
K65R Wild type 
recombinant 
clone 
CTCCAGTATTTGCAATAAAAAgGAAAGACAGTAC 
(K_4wd) 
TATTATATGGATTTTCAGGCCCAATTTTTG 
(Q5_mut_rev) 
M184V Wild type 
recombinant 
clone 
GTCATCTATCAATATgTGGATGATTTGTATG 
(M_4wd) 
TATTTCTGGATTTTGTGTCCTAAAGGGCTC 
(Q5_mv_rev )  
K65R+M184V K65R positive 
clone 
GTCATCTATCAATATgTGGATGATTTGTATG 
(M_4wd) 
 
TATTTCTGGATTTTGTGTCCTAAAGGGCTC 
(Q5_mv_rev ) 
A62V+K65R K65R positive 
clone 
CTCCAGTATTTGtAATAAAAAAGAAAGACAGTAC 
(A_4wd) 
TATTATATGGATTTTCAGGCCCAATTTTTG 
(Q5_mut_rev) 
A62V+M184V A62V positive 
clone 
GTCATCTATCAATATgTGGATGATTTGTATG 
(M_4wd) 
TATTTCTGGATTTTGTGTCCTAAAGGGCTC 
(Q5_mv_rev ) 
A62V+M184V 
+K65R 
K65R+M184V 
positive clone 
CTCCAGTATTTGtAATAAAAAAGAAAGACAGTAC 
(A_4wd) 
TATTATATGGATTTTCAGGCCCAATTTTTG 
(Q5_mut_rev) 
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Afterwards, each plasmid construct was transfected into 293T cells for virion production using the 
X-treme gene (Roche Diagnostics, South Africa) protocol described in section 2.5.1. The 
efficiency of transfection was confirmed using a fluorescence imaging assay described in the next 
section. The harvested virus of the A62V+K65R+M184V and K65R+M184V constructs, obtained, 
post-transfection, was then quantified using a TCID50 end point titration assay and using this the 
results of this assay a measure of the replication-competent infectious virion particles was then 
calculated and used in preparation for the growth competition assay. 
2.6.3 Assays to test infectivity and quantification of replication competent virus 
2.6.3.1 Fluorescence imaging assay 
To optimize the harvesting of virus, post-transfection, a fluorescence imaging assay targeting the 
expression of eGFP protein that is expressed by successfully transfected cells incorporating the 
recombinant plasmids was done. Setup of the assay involved growing 293T cells on 20 x 20 mm 
glass coverslips in a 6-well culture plate. The cover slips were first sterilised before use with a 
solution of 57% ethanol and 10% sodium hydroxide in petri dish following a prescribed protocol 
(Redig, 2013). Afterwards, these were rinsed with distilled water before further sterilization with UV 
light for 30 min under a UV cabinet hood (Nuaire, USA). In addition to UV sterilization the 
coverslips were then coated with 1mg/ml poly-Lysine (Sigma- Aldrich, USA) to allow attachment of 
293T-cells. Following transfection of the recombinant plasmids into each well on a 6 culture well 
plate, coverslips were extracted using sterile forceps and fixed with 4% paraformaldehyde for 10 
minutes before being rinsed with once with 1 x PBS and visualized for eGFP using a standard 
fluorescence microscope. The maximum peak in eGFP expression was then observed between 18 
- 48hrs to determine the optimal harvest point and to qualitatively establish the efficiency of the 
transfection experiment. After the optimal conditions for transfection had been identified, the 
transfection experiment was repeated to generate viral stocks for the recombinant plasmids 
constructs. Post-transfection, viruses were obtained by harvesting cell culture supernatant, 
followed by 10-minute centrifugation at room temperature at 1200rpm and afterwards storing the 
supernatant obtained in aliquots of 1 - 2ml at -20°C or -80°C for later use. 
2.6.3.2 TCID50 end point titration assays (A62V+K65R+M184V and K65R+M184V) 
TZM-bl cells were used to set up the TCID50 titration assay as they permit indirect quantification of 
replication competent virus by assaying for B-galactosidase enzyme activity for HIV-1 infected 
cells. Serial dilutions ranging from 102-106 for were prepared in 1.5ml Eppendorf tubes for the viral 
aliquots of the A62V+K65R+M184V and K65R+M184V viruses that were to be used in the growth 
competition experiment setup. Briefly, 900µl was pipetted into 1.5ml Eppendorf tubes marked from 
10-106 for each virus. 100µl of each viral aliquot was then added to the tubes labelled with the ten-
fold dilution. From there on, 100µl from the 10-fold dilution tube was then transferred to the tubes 
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marked 102. The procedure was repeated for each successive dilution in the dilution series up to 
the tube marked 106 to achieve a dynamic range of dilution from 100 – 1000000 times). TZM-bl 
cells were then seeded in a 96 flat bottomed cell culture plate as indicated in Figure 11. A total of 
two 96 flat bottomed cell culture plates were used – one for each virus and a total of 12 replicates 
for each dilution in the dilution series for each virus were used in the assay to attain a statistically 
accurate measure of the TCID50 value. The Spearman-Karber formula was applied to calculate 
TCID50 values for both viral mutants (A62V+K65R+M184V and K65R+M184V). The Spearman – 
Karber formula is described with the following equation: Spearman-Karber Formula = xk +d [0.5-
(1/n) r] - Where xk = dose of highest dilution; d = space between dilutions; n = number of replicates 
per dilution and r = total number of negative wells excluding negative controls. For the conversion 
of the TCID50 value to plaque forming units (PFUs), a conversion factor of 0.56 was used. This 
factor is a standard mathematical conversion factor to get the equivalent of replication-competent 
infectious virion particles as measured by the plaque forming assay. The results obtained were 
then used to normalize for the starting concentration of both viruses in the growth competition 
assay that would have an overall Multiplicity of infection (M.O.I) of 0.01. 
 
 
Figure 11. Layout for TCID50 end point titration assay for A62V+K65R+M184V and K65R+M184V 
with an indication of the number of cells seeded in each well for the assay 
1 2 3 4 5 6 7 8 9 10 11 12
A 10^2 10^2 10^3 10^3 10^4 10^4 10^5 10^5 10^6 10^6 Negative
B 10^2 10^2 10^3 10^3 10^4 10^4 10^5 10^5 10^6 10^6 Negative
C 10^2 10^2 10^3 10^3 10^4 10^4 10^5 10^5 10^6 10^6 Negative
D 10^2 10^2 10^3 10^3 10^4 10^4 10^5 10^5 10^6 10^6 Negative
E 10^2 10^2 10^3 10^3 10^4 10^4 10^5 10^5 10^6 10^6 Negative
F 10^2 10^2 10^3 10^3 10^4 10^4 10^5 10^5 10^6 10^6 Negative
G  
H Neat Neat
Key:
Negative controls (Uninfected wells)
Inoculated wells
Number of TZM_bl cells required per well = 0.5 x 10^5 cells
Total number of cells required for plate = Number of wells x 0.5 x 10^5 = 3.4 x 10^6
Total number of cells required for 2 plates = 2 x Number of wells x 0.5 x 10^5 = 6.8 x 10^6
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2.6.4 Allele-specific real-time qPCR assay design 
To accurately detect and differentiate the growth of A62V+K65R+M184V and K65R+M184V 
mutant HIV-1 BC recombinant viruses in the growth competition experiment, an allele-specific and 
probe-based real-time qPCR assay was designed.  
The qPCR assay used forward and reverse primers to amplify a ~140 - 170bp fragment targeting 
the reverse transcriptase gene region in which A62V and K65R mutations were introduced. Two 
forward primers were specifically designed. The first primer designated Total forward (T-Fwd) 
primer was designed to be able to detect the total virus that was to be assayed during the Growth 
competition experiment. This primer was different from another forward primer designated the 
Wild-type specific primer (WT-primer) that was specifically designed to detect viruses that did not 
contain the A62V mutation (A62V negative).This primer had the wild-type DNA nucleotide base in 
the position of the mutated base (A62V), making it specific for A62V-negative viruses (see Figure 
12 for an overview of the design).  
 
Figure 12. Overview of allele-specific real-time qPCR design. Primers for assay are indicated in 
purple arrows. 
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The difference between the total virus and the A62V-negative virus deduced from the combination 
of using the two primers in the qPCR assay will allow for the quantification of the A62V positive 
virus and further analysis of the growth kinetics of both A62V-negative and A62V-positive viruses. 
The WT-primer would specifically differentiate between A62V-negative and positive viruses by 
causing inefficient amplification of the A62V-positive virus due to the mismatched base, and this 
then gives a delay in the cycle threshold (Ct) value obtained during qPCR. The greater the Ct value 
delay, the greater the primer specificity and the greater the statistical confidence the primer has in 
the detection of wild-type (A62V-negative and also perfect matched template). For example, a Ct 
delay of 6 cycles during qPCR would mean that the assay is 66-fold more sensitive for the wild 
type target than the mutant as at 100% efficiency a target is amplified 10-fold each 3.3 cycles. 
Therefore 6 cycles would equate to 10(6/3.3) = 65.79. At 50% wild-type and mutant concentration, 
less than 0.5 x 1/66 ~ 1% of the wild-type signal could therefore be ascribed to a false positive 
(mutant template) signal. Using the T-forward primer (detecting wild-type and mutant) and wild-
type assay in parallel would therefore allow the accurate differentiation of variants harbouring the 
mutant vs wild-type by subtracting the wild-type signal from the total signal to obtain the mutant 
concentration as long as the Ct difference is large and the expected wild-type and mutant 
concentrations are the same range (as the false signal would also be affected by the proportion of 
the ‘false’ template, with a higher discrimination needed when the ‘false’ template is in excess 
relative to the ‘true’ template)(Bergroth et al.,2005).  
Setup of the assay was completed by the addition of DNA standards derived from the plasmid wild 
type and A62V-positive recombinant clones. DNA standards were prepared  by using a short 
fragment from the plasmids amplified using the infusion primers and Q5™ hot start PCR protocol 
(NEB,USA) described in section 2.6.1. The ~1505bp amplicon obtained was PCR cleaned up 
using the MiniElute reaction clean-up kit (Qiagen, Germany) and after that quantified and 
confirmed for purity on the NanoDrop™ ND 1000 spectrophotometer. After quantification of both 
wild-type and A62V, DNA amplicon stocks were confirmed to be at the same starting concentration 
regarding DNA copy numbers using data acquired from NanoDrop™ ND 1000 spectrophotometer 
and a DNA copy number calculator (Staroscik, 2004). Dilution series of both wild-type and A62V 
specific standards from 102-106 were made using wild-type and A62V plasmid amplicon stocks.
Serial dilutions of the standards were done following the same procedure for making 10 fold 
factor serial dilutions described in section 2.6.3.2 but with modifications which include using a 
volume to volume mix ratio of 20µl (plasmid amplicon solution) : 180µl (nuclease free water 
preheated to 56°C) mixed by pipetting up and down 20 times. After preparation, the standards 
were stored at -20°C for later use. 
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Optimization of the qPCR assay was completed by multiple runs done using master mixes 
specifically made up with either T–Fwd or WT-specific primers. In addition to the primers the 
master mix consisted of a TaqMan probe (using FAM as a fluorophore and BHQ™ as the 
quencher),1 Step Lo - Rox PCRbio real time master mix (PCR biosytems, USA) and the 
template that was either wild type or A62V mutant standards. The total volume of the reaction 
was 20 µl and the cycling parameters on the CFX96 real time PCR system (Bio-Rad, USA) 
were as follows: Reverse transcriptase (RT) incubation step at 50°C for 10 min, Initial 
denaturation at 95°C for 2minutes and 39 cycles of denaturation at 95°C for 10 seconds 
followed by elongation and extension at 60°C for 20 seconds. The standards were assayed in 
triplicate. The 1 Step Lo-Rox PCRbio real time master mix can be used for detection of either 
RNA or DNA templates because of the addition RT in the mixture and this has the direct 
advantage of quantifying viral RNA extracted from the cell culture growth competition 
experiment. 
2.6.5 Growth competition experiment (A62V+K65R+M184V vs K65R+M184V) 
The TCID50 values obtained using the TCID50 end point titration assay were used to calculate 
the amount of replication-competent A62V+K65R+M184V and K65R+M184V mutant viruses 
and the results were used to normalize the starting concentration of these viruses for the head 
to head growth competition experiment. The head to head growth competition experiment set 
up was finalized by seeding 5 x 105 TZM-bl cells per well in a standard 6-well culture plate, 
followed by 24hr pre- incubation of the 6-well culture plate in a humidified, 5% CO2 and 37°C 
incubator (Nuaire, USA). Three wells were used as biological replicates for the growth 
competition experiment and labelled accordingly.  
Two wells were used as positive controls that were inoculated with A62V+K65R+M184V and 
K65R+M184V viral aliquots respectively. The inoculum used represented an M.O.I. of 0.01. 
Viral supernatant from the growth competition experiment was harvested at time 0, 48 and 72hr 
following co-inoculation of the mutant viruses in the biological replicate and control wells 
marked on the plate and the supernatant was stored at -20°C for later extraction with the Qiamp 
Viral RNA extraction kit (Qiagen, Germany). Viral RNA was then quantified using the allele-
specific real-time qPCR assay optimized for running on the CFX96 real-time PCR system (Bio-
Rad, USA)  
For quality control purposes, two technical replicates were assessed in parallel for the same 
biological replicate’s RNA extract in the qPCR experiment. Three replicates for No template 
controls (NTCs) and cell culture negative controls harvested from the growth competition 
experiment were also included. 
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Analysis of qPCR experiment results was done using the standard curves method to assess 
reaction efficiency and the correlation coefficient for the assay. For the WT-primer allele-specific 
qPCR assay, mutant standards were included as false standards to check the specificity of the 
WT-primer. Statistical analysis with the Wilcoxon signed rank test in the program R v3.2.2 (R 
Development Core Team, 2008) for comparison of the relative fitness of A62V+K65R+M184V and 
K65R+M184V mutant viruses and the overall coefficient of variation (CV) was calculated to assess 
the assay’s reproducibility. Results also include growth curves for the two viruses and are 
presented in the next chapter. 
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Chapter 3 – Results 
 
Introduction 
The results are presented on a section by section basis following the same outline of the 
methodology described in the previous chapter and these include: - 
 Section 1-2 - Sequencing results for TV1-2kb and TV1-2.5kb wild-type and mutant subclones, 
and TV1-FLG; gag p24 HIV ELISA and X-gal staining for TV1-FLG results that were essential in 
testing the infectivity of the clone and to assess its potential to be used as a backbone vector to 
harbour the following mutation combinations: 
 A62V, 
 K65R, 
 M184V 
 A62V+K65R 
 A62V+M184V 
 K65R+M184V 
 A62V+K65R+M184V 
 
Section 3 - Infusion™ cloning and Q5™ mutagenesis results; fluorescence imaging and TCID50 
results; qPCR optimization and the growth competition results between A62V+K65R+M184V and 
K65R+M184V mutant viruses  
3.1 Sequencing results for TV1-2kb and TV1-2.5kb wild-type and mutant subclones  
Standard DNA Sanger sequencing was utilized to verify successful cloning of inserts (TV1-2kb and 
TV1-2.5kb) fragments as shown in Figure 13 and Figure 14, respectively. Sequences generated 
using the Big dye cycle sequencing kit (Applied Biosystems, USA) and run on the ABI 3130xL 
Genetic Analyser were analysed by Sequencher v5 (Gene Codes Corporation, Ann Arbor, MI 
USA) software. The read lengths of each sequence were an average of 485bp and the sequences 
were trimmed from the edges to remove low-confidence base calls and were about 98% quality 
(Addendum I). Verification of the presence of the desired mutations in the subclones (Figure 15 
and Figure 16) was confirmed using the Sequencher v5 program. 
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Figure 13. Contig tree drawn using Sequencher v 5. The top left red arrow indicates the reference 
TV1-2kb wild type sequence aligned to the primer generated sequences (line arrows shown below) 
that overlap each other and verify the presence of the insert in p-Gem T easy Vector. 
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Figure 14. Contig tree drawn using Sequencher v 5. The top right red arrow indicates the 
reference TV1-2.5kb wild type sequence aligned to the primer generated sequences that overlap 
each other and verify the presence of the insert in p-Gem T easy Vector. 
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Figure 15.Image cropped from Sequencher v5 showing base change confirmations (from C--> A 
highlighted in blue) for A62V mutation on A62V (1), A62V+ K65R (6), A62V+K65R+M184V (8-10), 
sample clones. Base change confirmation (from A--> G highlighted in blue) of K65R mutation on 
A62V+ K65R (6), A62V+K65R+M184V (8-10), K65R (2-4) and K65R+M184V (7) mutant clones. 
The wild-type reference sequence is indicated at the top and primer sequences aligned, are 
indicated at the bottom. (5) M184V sample clone. 
Stellenbosch University  https://scholar.sun.ac.za
53 
 
 
Figure 16. Base change confirmation (from A--> G highlighted in blue) of M184V mutation on 
M184V (5) sample, A62V+K65R+M184V (8, 9, 10) and K65R+M184V (7) mutant clones. The wild-
type reference sequence (top) and the primer for M184V mutagenesis (base mutation highlighted 
in red) are aligned to the sequences for further confirmation. A62V (1), A62V+ K65R (6)
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3.2 TV1-FLG 
3.2.1 Ligation and restriction enzyme digestion results 
Figure 17A below indicates gel photo of the two fragments needed for TV1-FLG synthesis prior to 
ligation and after ligation respectively. Figure 17B indicates restriction enzyme digestion 
confirmation of TV1-FLG cloning. The TV1-FLG HIV-1 subtype C constructs synthesized in this 
study was the final ligation product of the 5’ LTR-> start of env fragment (T5) from the consensus 
TV1 HIV-1 full genome sequence enzymatically digested and gel purified from the S clone and the 
env-> 3’ LTR of TV1 (J4) derived from the MJ4/TV1 hybrid clone. 
 
Figure 17A. Gel photos showing the linear fragments used for synthesis of TV1-FLG plasmid – J4 
(from MJ4/TV1 hybrid) and T5 (from S-clone). Right image shows confirmation of ligation for both 
the ligation control and TV1-FLG (TV1_Lig_j4+t5).
 
Figure 17B Gel photo showing restriction enzyme digestion confirmation of TV1-FLG. TV1-FLG 
plasmid is digested with a panel of restriction enzymes according to the expected map of TV1-FLG 
(shown in Addendum H). U1, U3 and U2 are uncut controls, digest samples 1-4 M = 1KB 
molecular weight marker (Promega, USA) 
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3.2.1 Sequencing results of TV1- FLG  
The TV1-FLG plasmid was partially sequenced (Figure 18) by primers targeting env and nef 
overlapping regions (HXB2 map positions 8526-9157 and 8766-9375 on TV1-FLG), 3’LTR end of 
HIV and the 5’LTR -> end of pol  
 
 
Figure 18 Image taken from Snap Gene software (GSL biotech, USA) showing binding positions of 
primers used for sequencing TV1-FLGs (labelled in purple) annealing to the TV1-FLG genome 
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Only one primer (Nef_f) yielded an env region sequence (Figure 19). Sequencing reactions using 
the other env –targeting primers were not successful, even after optimising conditions. 
Nevertheless, sequences were obtained for the 5’LTR – end of pol region of TV1-FLG (Figure 20). 
 
Figure. 19 Image taken from Geneious R6 showing sequences (indicated by black arrows) 
generated by primers (From top to bottom - Nef_f, U5Cc_F, 1.33ProC, 1.55PLC_f and M13 rev) 
annealing to the TV1-FLG 3’LTR and env and nef overlapping regions shown in red above. 
In each sequencing result for TV1-FLG, the primer sequences generated are also indicated with 
internal black markings that indicate mismatches or ambiguities in the sequence when cross 
referenced with the TV1 consensus sequence. Despite not being able to obtain a full genome 
sequence, the results suggest succesful cloning of the target region into the TV-1 backbone and a 
logical move to proceed to test for infectivity in cell culture using HIV- p24 antigen or X-gal staining 
assays. 
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Figure.20 Image taken from Geneious R6 showing sequences generated by primers annealing to 
the TV1-FLG 5’LTR – end of pol shown in red above. 
3.2.2 HIV gag p24 ELISA and X- gal staining results for TV1-FLG 
HIV p24 ELISA results (Figure 21) using the Quick Titer TM HIV Lentivirus Quantification kit (Cell 
Biolabs, Inc., San Diego USA) showed TV1-FLG to be no infectious in HEK 293T cells and this 
was further confirmed by X-gal staining in TZM- bl cells (Figure 22) 
 
Figure 21. TV1-FLG HIV-p24 concentration estimation using linear regression with known p24 
standards. The figure legend indicates the NL4.3 (positive control) plasmid, HIV p24 antigen 
standards, and TV1-FLG and MJ4/TV1 plasmids.  
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Figure 22. Image taken by a light microscope showing results for TV1-FLG X-gal staining. Blue 
cells are indicative of HIV-1 infection  
X-gal staining was negative for TV1-FLG but positive for NL4.3, pZAC and MJ4/TV1 hybrid 
plasmids. The image results represent the moderate staining in each of the respective wells that 
contained TZM-bl infected cells and images shown in figure 22 are the wells which were concluded 
subjectively to be the best representation of image analysis. 
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3.3 Results from plan to subclone in NL4.3 Subtype B infectious Plasmid 
Cloning and mutagenesis experiments resulted in HIV-1 BC recombinants. HIV-1C constructs with 
the gag-pol gene were derived from the MJ4 HIV-1C clone and could be used to assess HIV-1C 
mutation interactions.  
3.3.1 Infusion™ cloning and Q5™ mutagenesis results 
The MJ4 gag_pol gene (nucleotide positions 2010 -3493 on the HXB2 map) was successfully 
fused to the NL4.3 eGFP prepared vector and used as the starting template to derive all the full-
length genome (FLG) mutant recombinants required by the first objective of this study. In 
summary, a total of eight HIV-1BC recombinants were synthesized and confirmation of the 
constructs were obtained via PCR amplification of the inserts using the infusion primers designed 
for the study and DNA Sanger sequencing.  
Gel electrophoresis analysis after PCR amplification and DNA Sanger sequencing (specifically for 
M184V+K65R and A62V+K65R+M184V used in the growth competition experiment) results are 
shown in Figure 23 and Figure 24 (A-D). Images showing sequence results were taken using 
SnapGene program (GSL Biotech, USA) 
 
Figure 23. Gel photo showing PCR confirmation of HIV-1BC recombinants. The unamplified 
plasmids are also shown on the gel and serve as controls to verify the size of the full length 
genome (FLG) constructs. 
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Figure 24A. DNA Sangers sequencing results to show proof of insertion of M184V mutation on 
A62V+K65R+M184V construct using Q5™ Mutagenesis technique. 
 
 
Figure 24B. DNA Sanger sequencing results to show proof of insertion of K65R +A62V mutations 
on A62V+K65R+M184V construct using Q5™ Mutagenesis technique. 
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Figure 24C. DNA Sanger sequencing results showing proof of insertion of M184V mutation on 
K65R+M184V construct using Q5™ Mutagenesis technique. Reference sequence highlighted in 
blue and plasmid sequence highlighted in black 
 
Figure 24D. DNA Sanger sequencing results showing proof of insertion of K65R but not A62V 
mutation on K65R+M184V construct using Q5™ Mutagenesis technique. Reference sequence 
highlighted in blue and plasmid sequence highlighted in black 
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3.3.2 Fluorescence imaging results 
The optimal harvest point and validation of the transfection experiment for the HIV-1 BC 
recombinants was determined to be 22.5hrs post-transfection and fluorescence image results of 
the wild-type recombinant virus synthesised in comparison to pure Subtype B NL4.3 eGFP 
infectious virus are shown in Figure 25 below: 
 
Figure 25. Fluorescence image results to confirm validation of transfection experiment using 
synthesized recombinant constructs and lab adapted NL4.3 eGFP as a control. Green 
fluorescence expression of eGFP is indicative of successfully transfected cells. Images acquired 
22.5hrs post-transfection. 
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3.3.3 TCID50 end point titration results for A62V+K65R+M184V and K65R+M184V 
The TCID50 end point titration assay employing X Gal staining/ B- galactosidase detection in TZM-
bl cells for A62V+K65R+M184V and K65R+M184V mutant viruses showed K65R+M184V virus to 
be having a high concentration of replication competent virus. The results for both viruses were 
used to normalize for the starting concentration of the growth competition experiment between the 
two viruses. The plate results for both viruses obtained after the experiment are shown below: 
Plate A: - A62V+K65R+M184V X-gal staining/β- galactosidase detection in TZM-bl cells 
results 
 
 
Plate B: - K65R+M184V X-gal staining/β- galactosidase detection in TZM-bl cells results 
 
The TCID50 values for both viruses were calculated using the Spearman-Karber formula described 
in section 2.6.3.2 with data acquired from the plates and were 2.42E+03 and 6.32E+03 TCID50/ml 
and this is equivalent to 1.36E+03 and 3.54E+03 replication-competent copies per ml for 
A62V+K65R+M184V and K65R+M184V viruses respectively. The values were used to adjust the 
viral inoculums for the head to head growth competition experiment. 
1 2 3 4 5 6 7 8 9 10 11 12
A 10^2 10^2 10^3 10^3 10^4 10^4 10^5 10^5 10^6 10^6 Negative
B 10^2 10^2 10^3 10^3 10^4 10^4 10^5 10^5 10^6 10^6 Negative
C 10^2 10^2 10^3 10^3 10^4 10^4 10^5 10^5 10^6 10^6 Negative
D 10^2 10^2 10^3 10^3 10^4 10^4 10^5 10^5 10^6 10^6 Negative
E 10^2 10^2 10^3 10^3 10^4 10^4 10^5 10^5 10^6 10^6 Negative
F 10^2 10^2 10^3 10^3 10^4 10^4 10^5 10^5 10^6 10^6 Negative
G  
H Neat(AKM) Neat(AKM)
1 2 3 4 5 6 7 8 9 10 11 12
A 10^2 10^2 10^3 10^3 10^4 10^4 10^5 10^5 10^6 10^6 Negative
B 10^2 10^2 10^3 10^3 10^4 10^4 10^5 10^5 10^6 10^6 Negative
C 10^2 10^2 10^3 10^3 10^4 10^4 10^5 10^5 10^6 10^6 Negative
D 10^2 10^2 10^3 10^3 10^4 10^4 10^5 10^5 10^6 10^6 Negative
E 10^2 10^2 10^3 10^3 10^4 10^4 10^5 10^5 10^6 10^6 Negative
F 10^2 10^2 10^3 10^3 10^4 10^4 10^5 10^5 10^6 10^6 Negative
G  
H Neat(MK) Neat(MK)
Positive
Negative
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3.3.4 Allele-specific real-time PCR optimization results 
After optimization of the allele-specific real-time PCR assay, WT-primer detected specific WT 
product approximately 13 Cts before the mutant plasmid when assayed at the same concentration 
(whereas the total assay using the T-fwd primer quantified them equally). This provided a high 
specificity for the WT allele-specific assay as 13 Cts equates to a ~104 –fold difference in detection 
of the ‘true’ wild type signal vs the ‘false’ mutant signal. When used in parallel, the total assay 
could therefore be used to quantify reliably WT and mutant (by subtracting wild-type from the Total 
virus) concentrations. The qPCR assay was analysed using the Relative Standard Curve method 
with the Bio-Rad CFX manager software v3.1 (Bio-Rad, USA). The amplification plots and 
standard curves for the WT-primer are shown below (Figure 26 A-C) and include an individual and 
overall analysis of both the wild type and mutant standards to show a 13 Ct difference. Real time 
PCR results of the T-forward primer on the wild type and mutant standards is shown in Figure 26 
D The assay was in the accepted standard range for qPCR experiments with an average reaction 
efficiency of 107.5% and an R2 value of ≥0.98 and average slope of -3.2.No-template controls 
(NTCs) included did not give a signal ruling out the possibility of contamination in the experiments. 
 
 
Stellenbosch University  https://scholar.sun.ac.za
65 
 
Figure26A. WT primer analysis on wild type standards 
 
Figure26B. WT-primer analysis on Mutant (A62V) standards 
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Figure26C. Overall analysis of WT-primer on Wild type and Mutant (A62V) standards 
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Figure26D. T-fwd primer Wild type and Mutant (A62V) standards optimization The wild type and 
mutant amplicons are both detected at the same Ct value confirming that there are at the same 
concentration and non-specificity of the T-forward primer. 
 
3.3.5 Growth competition experiment results for A62V+K65R+M184V vs K65R+M184V 
The results obtained after qPCR analysis of A62V+K65R+M184V vs. K65R+M184V growth 
competition samples were analysed with Bio-Rad CFX manager software v3.1 (Bio-Rad, USA) 
before being exported to an excel file for graphical analysis and finally to program R v3.2.2 (R 
Development Core Team, 2008) for statistical analysis. The quantification data for the experiment 
is represented in Table J and the values are used to generate graphical results shown in Figure 
27. Table K shows the overall data and the raw values obtained after the qPCR experiment.
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Table J. Quantification data for head to head growth competition experiment using WT and 
T- Forward primers to detect M184V+K65R and both viruses respectively. 
Key: - blue = 1st replicate; lime green = 2nd replicate; grey = 3rd replicate; yellow = Geometric mean 
of 3 biological replicates at a given sampling time; Orange = values used to plot overall growth 
curves 
 
WT- primer Assay   T-Forward - primer Assay 
Replicates/time (hrs) Viral copies/qPCR rxn  Replicates/time (hrs) Viral copies/qPCR rxn 
G1 Geometric mean of 2 
technical replicates per 
sampling time 
 G1 Geometric mean of 2 
technical replicates per 
sampling time 
0 3.42E+04  0 1.72E+05 
48 1.52E+05  48 5.03E+05 
72 1.04E+05  72 3.49E+05 
     
G2   G2  
0 5.97E+04  0 2.40E+05 
48 1.32E+05  48 6.49E+05 
72 8.41E+04  72 4.20E+05 
     
G3   G3  
0 4.36E+04  0 1.14E+05 
48 1.55E+05  48 3.67E+05 
72 9.27E+04  72 2.26E+05 
     
 Geomean (G1+G2+G3)   Geomean (G1+G2+G3) 
0 4.46E+04  0 1.68E+05 
48 1.39E+05  48 4.93E+05 
72 9.68E+04  72 3.21E+05 
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Figure 27. Average growth curve plot for A62V+K65R+M184V vs. K65R+ M184V viruses. 
A62V+K65R+M184V growth curve is derived from the subtraction of K65R+M184V curve from the 
total growth curve generated from the T-Fwd primer qPCR assay. The growth curve values used to 
plot the curves are the arithmetic mean of the 3 biological replicates used in the head to head 
growth competition assay for the two viruses. Raw data is shown below in Table J. 
The experiment was validated for reproducibility by a calculation of the Coefficient of Variation (CV) 
which was found to be 13%. The CV-value given is computed using qPCR quantification data from 
the three biological replicates used in the growth competition experiment and is shown in the table 
K 
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Table K: qPCR quantification data for head to head Growth competition experiment for 2 
technical replicates for each of the 3 biological replicates 
. Key: - blue = time 0 data; lime green = time 48 data; grey = time 72 data; yellow = Geometric 
mean of two technical replicates of each biological replicate at a given time 
Sample Time Technical 
Replicate 
Time_Assay Ct Starting Quantity 
(viral copies/ qPCR 
rxn) 
Geo_Mean 
G1_0 0 1 0_Total 18.18 1.91E+05  
G1_0 0 1 0_Total 18.50 1.56E+05 1.72E+05 
G2_0 0 2 0_Total 17.79 2.45E+05  
G2_0 0 2 0_Total 17.86 2.35E+05 2.40E+05 
G3_0 0 3 0_Total 18.85 1.24E+05  
G3_0 0 3 0_Total 19.11 1.05E+05 1.14E+05 
G1_0 0 1 0_WT 19.79 4.57E+04  
G1_0 0 1 0_WT 20.64 2.56E+04 3.42E+04 
G2_0 0 2 0_WT 19.26 6.54E+04  
G2_0 0 2 0_WT 19.53 5.44E+04 5.97E+04 
G3_0 0 3 0_WT 19.35 6.15E+04  
G3_0 0 3 0_WT 20.36 3.09E+04 4.36E+04 
G1_48 48 1 48_Total 16.52 5.53E+05  
G1_48 48 1 48_Total 16.82 4.57E+05 5.03E+05 
G2_48 48 2 48_Total 16.19 6.86E+05  
G2_48 48 2 48_Total 16.36 6.14E+05 6.49E+05 
G3_48 48 3 48_Total 17.12 3.76E+05  
G3_48 48 3 48_Total 17.20 3.58E+05 3.67E+05 
G1_48 48 1 48_WT 18.01 1.54E+05  
G1_48 48 1 48_WT 18.48 1.12E+05 1.31E+05 
G2_48 48 2 48_WT 18.10 1.45E+05  
G2_48 48 2 48_WT 18.37 1.21E+05 1.32E+05 
G3_48 48 3 48_WT 17.95 1.61E+05  
G3_48 48 3 48_WT 18.04 1.50E+05 1.55E+05 
G1_72 72 1 72_Total 17.03 4.01E+05  
G1_72 72 1 72_Total 17.46 3.04E+05 3.49E+05 
G2_72 72 2 72_Total 16.77 4.73E+05  
G2_72 72 2 72_Total 17.14 3.73E+05 4.20E+05 
G3_72 72 3 72_Total 17.92 2.26E+05  
G3_72 72 3 72_Total 17.93 2.25E+05 2.26E+05 
G1_72 72 1 72_WT 18.37 1.21E+05  
G1_72 72 1 72_WT 18.48 1.12E+05 1.16E+05 
G2_72 72 2 72_WT 18.72 9.47E+04  
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Table J continued 
G2_72 72 2 72_WT 19.07 7.47E+04 8.41E+04 
G3_72 72 3 72_WT 18.61 1.03E+05  
G3_72 72 3 72_WT 18.90 8.38E+04 9.27E+04 
 
The geometric mean of two technical replicates obtained from each biological replicate in the 
growth competition experiment was used as variables to calculate the relative fitness of each virus 
using the formula described in Chapter 1 section 1.4.2. A relative fitness Box and whisker plot 
(Figure 28) derived from the statistical analysis of the two viruses using the Wilcoxon signed rank 
test showed that there is no significant difference in the relative fitness of A62V+K65R+M184V 
compared to K65R+M184V mutant viruses.  
 
Figure 28. Relative fitness plot of A62V+K65R+M184V vs K65R+M184V 
Results are discussed in the next chapter. 
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Chapter 4 – Discussion 
4.1 Summary and significance of major findings 
The major finding of this study is that A62V mutation does not have a significant effect on viral 
fitness when it co-occurs with M184V and K65R. This is unexpected as previous work suggested 
that A62V restored fitness loss conferred by K65R in the presence of S68G by increasing the rate 
of incorporation of natural dNTPs during HIV-1 reverse transcription (Svarovskaia et al., 2008). 
There are a few differences between the reported findings and our setting. 1) A62V and S68G 
occurred in patients treated with stavudine, abacavir or didanosine (Roge et al., 2003); 2) In our 
setting A62V was observed to co-occur with K65R and M184V; 3) Previous reports were in 
predominantly HIV-1 subtype B populations, whereas our patient population is predominantly HIV-
1 subtype C. M184V is a primary drug resistant mutation and like K65R causes reduced 
susceptibility of 3TC, FTC, ddi, ABC and diminished RT processivity and natural dNTP 
incorporation (Wainberg, 2004). M184V in combination with K65R reduces viral fitness more than 
any of the mutations on their own. It is possible that A62V may have had an effect on the fitness of 
K65R without M184V, which was negated by an interaction with M184V but this would not explain 
the co-occurrence of the three mutations. Other explanations are that A62V contributes to TDF 
resistance or that the fitness benefit is dependent on other accessory mutations being present. 
In an earlier study (Maeda et al., 1998), the A62V mutation was inferred to compensate for viral 
fitness when it occurred in concert with Q151M, F116Y, F77L and V75L mutations, however the 
study compared mutant viruses using invitro kinetic assays that do not model the relative fitness 
accurately compared to growth competition experiments and may have incorrectly overestimated 
the extent to which A62V acts as a compensatory mutation. In comparison, the head to head 
growth competition experiment in this study between A62V+K65R+M184V and K65R+M184V 
allowed a direct comparison of the two viruses under similar conditions. The high sensitivity of a 
growth competition experiment coupled with the high precision for quantification of growth kinetics 
with real-time PCR; make it unlikely that the negative finding on A62V is due to analytic error. 
However there is a possibility that A62V fitness interaction might not have been sensitively 
detected as major drug resistance mutations like M184V have a fitness loss of only 6% (Wainberg, 
2004) and compensation in fitness loss by A62V may not be sensitively detected by the qPCR 
assay employed in this study. 
With reference to TDF resistance the Stanford University HIV drug resistance database (Stanford 
HIVDB - http://hivdb.stanford.edu/) resistance interpretation algorithm assigns a score of 5 to the 
A62V mutation when it occurs alone and an additional score of 10, with a net score of 15 when it 
co-occurs with K65R. 
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Although no peer-reviewed publication provides evidence of the effect of A62V on TDF resistance, 
the Stanford DB scoring suggests that it may have a synergistic effect on drug resistance when co-
occurring with K65R. Phenotypic data on its effect on TDF resistance in HIV-1 subtype C would be 
informative. 
In the presence of K65R, TDF has been reported to retain activity, probably due to the moderate 
effect of K65R on drug resistance and its effect on viral fitness impairs viral replication (Grant et al., 
2010). In many African settings therapy monitoring relies on clinical and or immunological 
monitoring and virologic failure could remain undiagnosed. In these patients secondary mutations 
following M184V and K65R, such as A62V could accumulate. If secondary mutations would 
contribute to higher levels of TDF resistance or fitness compensation, the result could lead to 
higher levels of viral replication and clinical or immunological deterioration. Such accumulation of 
secondary drug resistance mutations has been reported for patients receiving thymidine analogue- 
and protease inhibitor-containing regimens but the role of A62V in reducing the benefit of TDF 
therapy in patients with failure is unknown. 
4.2 Other important findings/ Technical lessons learned 
Other results obtained in this study indicate the technical challenges that should be considered 
when developing a growth competition assay for the study of viral fitness. The wild-type and 
mutant subclones obtained as a result of section 1 and 2 of the methodology of the study represent 
the essential components of a phenotypic assay. The logical workflow for the synthesis of the 
mutant clones was based on the initial use of traditional- cloning methods that allow synthesis of 
full-genome mutant constructs by subcloning. The technique of subcloning small fragments to 
eventually derived large plasmids has been widely used in some studies (Louder et al., 2005; 
Rodriguez et al., 2006).  The advantage of using a subclone is that it provides a simple target 
template for efficient site-directed mutagenesis and it also provides the use of unique restriction 
enzyme sites that can be used to introduce the mutated sequence in a backbone vector construct 
harbouring the same restriction sites. The template size of an ideal subclone has to be relatively 
small to prevent non-specific binding of mutagenic primers (Carter, 1986). A small template also 
decreases the probability of the number of methylation sites that are known to direct mismatch 
repair systems in bacterial competent cells which will abrogate the intended mutation (Weiner et 
al., 1994). These factors explain in part why in this study, SDM on the TV1-2kb (~5122bp) clone 
using the Quick Change XL SDM kit (Stratagene, USA) was only successful to produce the M184V 
subclone and failed to synthesise the other mutant constructs regardless of efforts to optimize the 
experiment.  This suggests that perhaps the optimal size of a subclone for SDM using the Quick 
Change XL kit (Stratagene, USA) is below the size of the TV1-2kb subclone. However other factors 
such as primer design, fidelity and DNA processivity of the enzyme used during the SDM reaction 
could have also contributed to technical challenges experienced in trying to optimize the reaction. 
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Particularly, enzyme processivity was observed to significantly impact the outcome of the 
mutagenesis reaction. The observation was specifically experienced when synthesizing full-length 
recombinant constructs using the Q5™ mutagenesis kit (NEB, UK) in section 3 of the 
methodology. Section 3 of the methodology highlights another technical lesson learnt on the use of 
traditional based cloning methods using restriction enzymes compared to seamless advanced 
cloning methods such as the Infusion™ cloning (Clontech, USA). Infusion™ cloning minimized the 
technical challenges of cloning the large (1505bp) into the NL4.3 eGFP vector and compared to 
the previous approach using subclones, there was fast turnaround time for cloning the fragment 
(that is ~30 minutes compared to two days using traditional-based methods). More than 95% 
precision was observed in obtaining the recombinant clone and less time was spent on 
optimisation and troubleshooting.  
The use of real-time PCR for the growth competition experiment between A62V+K65R+M184V 
and K65R+ M184V viruses also simplified the growth competition setup as it did not require 
different reporter inserts and allowed a high precision as evident from the reproducibility of the 
assay.  (Dykes et al., 2006; Wang et al., 2010). The high specificity obtained for the allele-specific 
qPCR assay in this study (~13 Ct difference) and sensitivity (detection limit of 100 copies/ qPCR 
reaction) allows direct comparison of the findings in this study and for them to be comparable to 
other studies (Bergroth et al.,2005; Svarovskaia et al.,2008) employing similar approaches  
Another important finding was on the TV1-FLG plasmid (which was the initial backbone vector to 
introduce different combinations of A62V, M184V, K65R) turned out to be non-infectious. The 
probable cause of non-infectivity in cell culture (as validated by a negative result obtained in X-gal 
staining of TZM-bl cells and no detectable p24 antigen content with the HIV p24 ELISA assay) is 
possibly due to mutations in the gag/ pol  genes (shown in the sequence results obtained). The 
mutations in the gag/pol region were defined as such because of base mismatches with the TV1 
consensus sequence. TheTV1 env consensus sequence which was shown to code a for functional 
env gene (Jacobs unpublished data) and partially proven in this study by the growth of the 
MJ4/TV1 hybrid plasmid clone in TZM-bl cells also provided supporting evidence that non-
infectivity was probably caused by gag/pol mutations as the env was derived directly from MJ4/TV1 
plasmid.  Although mutations were also found in the TV1- FLG env, difficulty in sequencing this 
region with the primers that were available makes it difficult to conclude whether these mutations 
had a role in non – infectivity of the plasmid in cell culture.  However, the possibility still remains 
that they could have had an effect as deleterious env mutations could hinder HIV-1 receptor and 
co-receptor binding rendering cells immune to HIV-1 infection (Louder et al., 2005). 
Stellenbosch University  https://scholar.sun.ac.za
75 
 
The mutations of TV1-FLG plasmid found in the protease and RT coding genes could have a 
deleterious effect, resulting in non-functional proteins being expressed which in turn result in 
defective virions with poor infectivity in cell culture and the explanation is also supported by 
literature (Kozisek et al., 2012). 
Had TV1 – FLG proven to be infectious, it would have been a suitable HIV-1 subtype C backbone 
vector and mutations could have been introduced via homologous recombination and ligation from 
an intermediate plasmid (designated ‘carrier plasmid’ in the study) or direct ligation of PCR 
amplified mutated fragments from the TV1-2kb mutant sub clones. However, the technique of 
directly ligating PCR amplified fragments generated with homologous restriction sites to the vector 
is only a convenient way to synthesize full- length genome constructs, only if suitable unique 
restriction enzyme sites are present in the amplicon and vector, otherwise a subclone would be 
required. There was also a strong motivation to have a subtype C infectious clone. Given that there 
are only a limited number of HIV-1C plasmid constructs that have been published and these 
include five that are naturally derived (Mochizuki et al.,1999; Ndungu et al., 2000; Grisson et 
al.,2004; Dash et al.,2008; Jacobs et al., 2012) and a one that is synthetically made (Nauwelaers 
et al., 2011). Naturally derived wild-type HIV-1C molecular clones have been reported to have poor 
growth in cell culture (Jacobs, 2013 personal communication) and may not be ideal representatives 
to study viral fitness interactions.  Although there is a report of in-vitro synthesis of an HIV-1C 
infectious clone (Nauwelaers et al., 2011) with comparable growth kinetics to HIV-1B and HIV-1C 
clones, synthetic chemical processes lack the means to introduce certain natural intrinsic 
properties associated with DNA such as methylation. DNA Methylation affects the epigenetic 
control of genes regulated by transcription factors in vitro or in vivo (Lim and Maher, 2010; Moore 
et al., 2013). DNA methylation could have played a part in the non-infectivity of TV1-FLG in this 
study as half of the genome was derived from a synthetically non-methylated construct (TV1_S-
clone).  
4.3 Strengths and Limitations of study 
The key strength(s) of the study include significant advances in technical expertise and the 
understanding of the requirements needed to construct full-genome plasmid constructs for 
phenotypic drug resistance profiling. Such advances are reflected by achievements in 
troubleshooting cloning reactions; optimization for rapid ligation of large fragments; determining 
limiting factors for most commercially used SDM kits and the knowledge of more efficient cloning 
methods. The use of a highly reproducible allele-specific qPCR assay and the simple approach 
taken to set up a growth competition experiment proved to be a critical strength in this study assay, 
however, significant time was lost at the beginning of the study using traditional cloning methods 
and the need to synthesize a pure HIV-1C backbone vector to evaluate fitness interactions. 
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4.4 Further investigations to consider for future studies. 
Our results did not explain the co-occurrence of M184V, K65R and A62V.  Further investigations 
would be required to investigate the fitness effect of the individual mutations and all the possible 
mutation interactions: A62V vs. K65R; A62V vs. M184V; A62V vs wild-type viruses; A62V vs. 
A62V+K65R; A62V vs. A62V+M184V; A62V+K65R+M184V vs. K65R+M184V and 
A62V+K65R+M184V vs. wild-type in the presence of TDF. In addition, experiments to investigate 
the effect of A62V alone and in combination with K65R and/ or M184V on phenotypic drug 
resistance would assess whether an increased drug resistance conferred by A62V would be the 
basis for its selection in these patients.  
As genomic interactions outside the gene of interest (e.g. protease inhibitor resistance mutations 
and gag) could influence the net effect of a mutation, an infectious HIV-1C clone would be valuable 
for future experiments. This would allow assessing these mutation interactions in a backbone that 
represents the current circulating HIV-1 subtype C strains in the southern African region.  These 
further experiments fell outside the scope of the study (based on time limitations and funding).  
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Chapter 5 - Conclusion  
A62V reverse transcriptase mutation in HIV-1 has no significant fitness compensation effect when 
it co-occurs with M184V and K65R. However, further investigations are needed to characterise the 
mutation in the context of other accessory or secondary mutations commonly occurring in HIV-1 
subtype C to further explore fitness interactions. The effect of A62V when occurring alone or in 
combination with K65R and /or M184V also requires investigation. The investigation would be 
greatly aided by an infectious naturally derived pure HIV-1C molecular clone. The use of a highly 
reproducible qPCR assay to characterise growth kinetics of different constructs used in a growth 
competition experiment would facilitate such work. As an increasing number of patients receive 
TDF-based regimens it would remain a priority to study the accumulation of mutations on this 
regimen and their effect on fitness and drug resistance.  
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Addendum B – Summary of major reagents, software and equipment used in the study 
 
Material Application/ 
Methods 
Supplier Local Distributer 
(South Africa) 
Reagents    
Lab consumables – PCR  
Eppendorf tubes, pipette 
tips, culture flasks 
Various Laboratory 
standard techniques 
 WhitSci (Whitehead 
Scientific_Pty_Ltd) 
Qiamp Viral RNA 
extraction Kit 
Viral RNA extraction Qiagen, Germany WhitSci (Whitehead 
Scientific_Pty_Ltd) 
Go-Taq Long-range PCR 
system 
PCR experiments Promega, USA Anatech Instruments 
_Pty_Ltd 
Restriction enzymes Restriction enzyme 
digestion and cloning 
New England Biolabs, USA Inqaba Biotec 
Oligonucletiodes qPCR, PCR, Infusion™ 
cloning and Mutagenesis 
Inqaba Biotec Inqaba Biotec 
MiniElute reaction clean-
up 
PCR amplicon and gel 
extraction clean-up 
Qiagen, Germany WhitSci (Whitehead 
Scientific_Pty_Ltd) 
QiaxII gel extraction kit PCR amplicon and gel 
extraction clean-up 
Qiagen, Germany WhitSci (Whitehead 
Scientific_Pty_Ltd) 
Infusion™ Cloning Kit Cloning Takara-Clontech, USA Separations, South 
Africa 
Q5™ Mutagenesis kit Mutagenesis New England Biolabs, USA Inqaba Biotec 
Maxiprep™ System kit Preparation of plasmid 
maxiprep Stocks 
Promega, USA Anatech Instruments 
_Pty_Ltd 
Miniprep™ System kit Preparation of plasmid 
maxiprep Stocks 
Promega, USA Anatech Instruments 
_Pty_Ltd 
1 Step Lo-Rox PCRbio 
real-time master mix 
qPCR experiments PCR Biosystems, USA Biocom Biotech 
Q5™ hot start PCR 
system 
PCR experiments New England Biolabs, USA Inqaba Biotec 
X-treme gene HD 
Transfection reagent 
Transfection in cell 
culture assays 
Roche diagnostics, 
Switzerland 
Roche, South Africa 
Expand Hi-fi PCR System PCR experiments Roche diagnostics, 
Switzerland 
Roche, South Africa 
Competent cells (NEB-5 
alpha) 
Cloning New England Biolabs, USA Inqaba Biotec 
Competent cells (JM109) Cloning Promega, USA Anatech Instruments 
_Pty_Ltd 
Competent cells (Stable™ 
2) 
cloning Invitrogen, USA Life Technologies, 
South Africa 
    
  Major Equipment    
NanoDrop ™ ND 1000 Spectrophotometric 
measurements of DNA or 
RNA 
ThermoScientific, USA  
UV- ITEC Prochem Gel 
Dock System 
Gel visualization and 
imaging 
Cambridge, UK  
CFX96 Real- time PCR qPCR experiments Bio-Rad, USA Bio-Rad, South Africa 
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System 
Applied Biosystems 
Veriti® PCR thermal 
cycler 
PCR experiments ThermoFisher, USA Life Technologies, 
South Africa 
TC20 Automated cell 
counter 
Cell counting in cell 
culture assays 
Bio-Rad, USA Bio-Rad, South Africa 
 
 
ELx800™ ELISA plate 
reader 
Enzyme Linked 
Immunosorbent assays 
Bio-Tek, USA  
ABI 3130xL Genetic 
Analyser 
Sequencing Applied Biosystems, CA, 
USA 
 
CO2 Incubator Cell culture assays Nuaire,USA   
CO2 Shaker incubator Bacterial cultures Labcon, USA  
    
Software    
SnapGene Molecular analysis GSL biotech, USA 
 
 
Sequencher v 5 Sequence analysis Gene Codes Corporation, 
Ann Arbor, MI USA 
 
Ugene Cloning analysis Unipro, Novosibirsk, 
Russia 
 
Bio- Rad CFX Manager qPCR analysis Bio-Rad, USA Bio-Rad, 
 South Africa 
R program v 3.2.2 Statistical analysis R Development Core Team 
(https://www.r-
project.org/)  
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Addendum C1 –TV1 4.5kb proof 
 
 
Key: - C – Control, N = No template control, M = 1kb molecular weight marker. 4.5kb PCR prodcuts shown 
for different temperatures (°C) used 
 
Addendum C2 – MinElute Reaction Protocol (Qiagen, Germany) 
Procedure: 
 The protocol was followed by addition of 300μl of Buffer ERC to 20μl per enzymatic reaction volume 
followed by mixing. If the color of the mixture was orange or violet, 10μl of 3 M sodium acetate, pH 5.0 
until the color of the mixture would turn to yellow. This was then followed by inverting the tube 4-5 times 
to mix the contents. A MinElute column was then placed in a 2 ml collection tube in a suitable rack and the 
sample was then added to the column before subsequent centrifuging*  for 1min.To obtain maximal 
recovery, r all traces of sample were transferred to the spin column and the procedure repeated before the 
flow through was discarded. The MinElute column was then placed back into the same 1.5ml Eppendorf 
tube. Washing was done by addition of 750μl Buffer PE to the MinElute column and centrifuged for 1 min. 
The flow through was discarded and the tube was centrifuged again to remove any residual wash buffer. 
Afterwards the column was then placed in a new Eppendorf tube and 10μl elution buffer (preheated to 
50°C) 
 *All steps for centrifugation were carried out at 13000rpm 
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Addendum D1 –T4 DNA Ligation protocol 
 
1. Reaction assembly in a sterile microcentrifuge tube: 
Vector DNA        100ng 
Insert DNA        17ng 
Ligase 10X Buffer       1μl 
T4 DNA Ligase (Weiss units)      0.1–1u 
Nuclease-Free Water to final volume of     10μl__ 
2. Incubate time for reaction: 
Room temperature for 3 hours, or 4°C overnight, or 15°C for 4–18 hours. 
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Addendum D2 – plasmid maps for Tv1 subclones
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Addendum E – Sequencing protocol 
 
Big dye cycle sequencing kit v3.1 (Applied Biosystems) optimized protocol 
Sequencing reaction setup in a sterile 1.5ml 
Eppendorf tube 
Control reaction  
DNA Sample*  10µl DNA Sample*  1µl 
X terminator 1µl X terminator 1µl 
Double distilled H2O 3µl Double distilled H2O 4µl 
5 x Buffer 4µl 5 x Buffer 3µl 
Primer  2µl Primer  1µl 
Total 20µl Total 10µl 
*DNA samples had varying concentrations but the final volume of 10µl was made to a minimum of 400ng 
for miniprep plasmid DNA 
 
Addendum F – Restriction enzymes digest protocol 
 NEB Double digest Protocol (New England Biolabs, USA) 
DNA Sample (1µg)  2µl 
Nuclease free H2O 41µl 
Enzyme 1 (10 units)   1µl 
Enzyme 2 (10 units)   1µl 
5 x Cutsmart buffer   5µl 
Total 50µl 
    Incubation at 37°C for 1hr 
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Addendum G1 - SDM – PCR round 1 
 
    
Addendum G2 - SDM- PCR round 2 
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Addendum H –TV1_FLG map 
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Addendum I _Sequence quality proof 
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